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ABSTRACT 
  
Background and purpose: Ischemic Heart Diseases (IHD) are the most common cause of 
morbidity and mortality. Incidence and prevalence is continuously growing. There is an 
escalating risk for revascularization or resuscitation in patients with IHD. Recently, it has 
been reported that sphingosine 1-phosphate receptor agonist plays anti-apoptotic and anti-
inflammatory role in ischemia-reperfusion injury. The aim of our study is to investigate the 
cardioprotective effects of sphingosine 1-phosphate receptor agonist fingolimod (FTY720) 
in global ischemia-reperfusion injury related to the cardiac arrest, cardiopulmonary bypass, 
and heart transplantation. 
Methods: In all the three experimental studies, global ischemia-reperfusion was achieved 
by cardiac arrest either by Ventricular fibrillation or cardioplegia (CPB HT) in anesthetized 
(sodium pentobarbital, 60 mg/ml/kg i.v) and ventilated male Sprague-Dawley rats (300 - 
350 g). The global ischemic period lasted 10 min in the cardiac arrest and cardioplegic 
arrest, but in transplantation, ischemia time was 60 min while reperfusion times were 
maintained for either 60 min or 24 hours.  Where applicable, monitoring was done using 
electrocardiogram and hemodynamic data recorded at baseline, 1 hour and 24 hours of 
reperfusion. The level of high energy phosphates was measured. Apoptotic, inflammatory 
and oxidative markers were analyzed.  The statistical significance was considered as p ≤ 
0.05. 
Experimental design: In all the above mentioned protocols, 15 animals were used in each 
of the control and treated groups. The first study examined the cardioprotective potential of 
fingolimod using the following treatment strategy, treatment administered (post ischemia) 
immediately at the early phase of reperfusion (fingolimod 1mg/kg i.v) compared to saline 
controls (0.9% saline).  In next two experimental models, treatment administration was done 
15 min before ischemic phase (fingolimod 1mg/kg i.v.) compared to controls (0.9% saline), 
followed by 10 min ischemia and 60 min reperfusion in cardioplegic arrest while  60 min 
ischemic phase remained from heart explantation to reperfusion, and reperfusion phase 
lasted for 24 hours following blood and tissue collection 
Results:  Three experimental models demonstrated significant myocardial protection in 
Fingolimod treated groups as compared to control groups. Hemodynamic assessment 
showed improved cardiac function at late phase. Reduced frequency of apoptotic cells and 
inflammatory mediators were found in the treated group. High energy phosphates were 
preserved in the treated as compared to control groups. Reactive Oxygen Species (ROS) 
were also attenuated in the fingolimod-treated group. Increased phosphorylation of Akt and 
Erk1/2 signaling pathways found in fingolimod treated group as compared to control, these 
are important part of  Reperfusion Injury Salvage Kinase (RISK) and Survivor Activating 
Factor Enhancement(SAFE) pathways.  
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Conclusions: The intravenous administration of fingolimod in global ischemia-reperfusion 
was cardioprotective. Fingolimod cardioprotection appears to be mediated through 
preservation of high energy phosphates, reduction in oxidative stress, inhibition of apoptosis 
and inflammation leading to preserved cardiac functions. 
 In summary, targeting sphingosine 1-phosphate receptors modulation may offer a new 
potential therapeutic cardioprotective agent to attenuate myocardial damage during global 
myocardial ischemia and reperfusion.         
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SECTION-IA 
1. Introduction- Myocardial Ischemia 
Reperfusion Injury 
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Cardioprotection 
Cardiovascular diseases are the most common cause of mortality and an estimated 
17.5 million people died last year worldwide i.e., one-third of global deaths (World 
Health Organization, 2016). About 2.19 million deaths in Europe every year are 
attributed to ischemic heart diseases (World health federation, 2016). In Europe, Italy 
is performing the second highest number of cardiac procedures over 100 thousand in 
2014 (Eurostat, 2016). The last century has provided major advances in 
cardiovascular science from non-invasive procedures to interventional, Coronary 
Artery Bypass Graft (CABG) surgery and cardiac transplantation. In spite of all 
major advancements, cardiovascular diseases are still the most commonly growing 
cause of morbidity and mortality in developing as well as developed world. It poses a 
huge financial burden on the health care management system. Unfortunately, basic 
cardiovascular science could not achieve a goal of cardioprotection in the era of 
growing cardiovascular diseases with poor outcomes because of failure in potential 
basic research translation into clinical settings. Currently, the hot topic of research 
and discussion is “ Myocardial ischemia-reperfusion injury” to prevent irreversible 
myocardial damage to protect ventricular dysfunction that is leading cause of heart 
failure. Indeed, recent advances like ischemic pre and post conditioning encourage 
and optimize toward finding discoveries such as ischemic preconditioning have 
opened more doors than they have closed and enhanced optimism towards finding 
the eventual “cardioprotective” mechanisms. The cardioprotection usually defined 
as “all mechanisms and means that contribute to the preservation of the heart by 
reducing or even preventing myocardial damage. 
The research work presented in this thesis adds knowledge in cardiovascular science 
about cardioprotection by investigating the effect of sphingosine 1-phosphate 
agonist fingolimod in different global ischemia-reperfusion in-vivo models. 
1.1. Brief overview of Myocardial Ischemia 
Ischemic myocardial damage results from an inadequate supply of oxygen and 
nutrients to the myocardium. It is a pathological picture found in a variety of 
scenarios concerning the heart as in myocardial infarction in the territory, during 
cardiac surgery to intervene in the heart beating and heart transplant
1
. 
Since the myocardium is highly dependent on proper coronary perfusion, the sudden 
interruption of the latter rapidly leads to the anaerobic metabolism, depletion of 
high-energy phosphates and the onset of anaerobic glycolysis. A quick and early 
restoration of blood flow in the ischemic tissue is, therefore, essential in all patients 
that present different conditions associated with local or global interruption of blood 
flow, to secure recovery of cells if the damage from these immediately is reversible; 
Reperfusion, despite the undeniable utility, is associated with multiple adverse 
changes at the cellular level. Consequently, reperfused tissues may lose an additional 
number of cells in addition to those already damaged by ischemia. Reperfusion itself 
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can cause damage to the cardiomyocytes, increase the oxidative phenomena and 
induce apoptosis; this iatrogenic damage can go to constitute up to 50% of the total 
area of necrotic myocardium
2, 3
. 
Therefore, considering  the counterproductive implications of  myocardial 
reperfusion injury, there is absolute need to put the research to discover new 
pharmacological approaches aimed at reduction in the incidence of  heart failure, left 
ventricular dysfunction as much as possible on cardiac remodelling and improve the 
survival of patients who suffered a myocardial ischemic event 
3,4
. 
1.2. Circulatory Arrest 
Circulatory arrest is a state of cessation of a mechanical heart activity, confirmed by 
no pulse, with immediate termination of the blood flow, leading to a rapid depletion 
of oxygen, with depression of brain function and then loss of consciousness, sleep 
apnea or agonal breathing in patients on the territory or in patients already 
hospitalized
5
. Cardiac arrest is further differentiated into two sub divisions, nonfatal 
and fatal cardiac arrest, by responsiveness or not, to maneuvers of Basic Life 
Support (BLS) or Advanced Cardiovascular Life Support (ACLS). The incidence of 
cardiac arrest in the hospital varies according to the type of construction, type of 
hospital patients and the presence of a primary care team and oscillates between 1 
and 7%
6, 7
 with survival that is around 20%
8-11
.Mortality at a distance varies 
according to age, pathology and neurological status of patients after discharge from 
the hospital, and is higher in adults than paediatric population (27% versus 18%)
8
. 
The cardiac causes are the most frequent etiology for cardiac arrest that comprise 
63%
12
, of which 35% is contributed by myocardial infarction, 15% pulmonary 
causes, and 22% by other causes.  Other causes includes valvular heart disease, 
congenital,  myocarditis and cardiac tamponade
12
.  
Extra cardiac causes includes severe acute respiratory failure, severe hypoxemia, 
severe respiratory insufficiency, pulmonary edema, pulmonary embolism, dissection 
or rupture of the aorta, cerebral haemorrhage, marked bleeding, sepsis, serious 
electrolyte disturbances (hypo/hyperkalemia) and poisonings or side effects of 
medications or anesthetics
13, 14
. 
About cardiac causes, these alterations include either electrical impulse, or 
mechanical barriers, and in the case that the Genesis is primitively of one kind or 
another, you determine finally the ineffectiveness of both components. The most 
common electric mechanism is represented by Ventricular Fibrillation (VF), 
followed by asystole, pulseless electrical activity (Electromechanical dissociation,) 
in which the ECG detects electrical activity, but there is no effective cardiac output, 
or pulseless Ventricular Tachycardia (VT). The mechanical mechanisms include the 
rupture of the ventricle, pericardial tamponade, mechanical obstruction of a coronary 
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artery and the acute rupture of a large caliber vessel.The immediate consequence is 
the absence of systemic perfusion. The acute myocardial infarction is characterised 
by an evident myocardial necrosis that presents clinically as
15
:  
1. Patient death preceded by a typical symptom of myocardial ischemia and 
electrical signs of ischemia or Left Bundle Branch Block (LBBB) not present in 
previous ECG, before a possible check of positivity of biochemical markers of 
myocardial damage. 
2. Raising or reduction of fingolimod markers higher than 99 percentile of reference 
values, accompanied by at least one of the following: 
-      Symptoms related to myocardial ischemia 
-      Appearance of Q waves on ECG  
-      ECG appearance of T wave abnormalities or myocardial infarction or LBBB 
-      The appearance of myocardial substance loss or alterations of motility of the 
ventricular walls highlighted with ultrasound or other myocardial imaging tests. 
-       Coronary thrombosis or any possible stent, highlighted with coronary 
angiography or an autopsy 
3. Following the intervention of coronary angioplasty or stent placement if: 
Increase Troponin C (cTn) (> 5x99 percentile values) in patients with normal 
baseline or 2% increased of baseline values for patients with baseline values 
increased and simultaneous presence of symptoms related to myocardial 
ischemia, appearance of Q waves on the ECG, appearance of alteration of the T 
wave, myocardial infarction, LBBB, myocardial, ventricular dyskinesias, 
substance loss , evidence of coronary thrombosis and eventual stent, or in case of 
specific complications during the procedure. 
4. Following coronary artery bypass surgery 
Increase of cTn (10x99 percentile > reference values) in patients with normal basal 
values and simultaneous presence of presence of symptoms related to 
myocardial ischemia, or appearance of Q waves on the ECG, or appearance of 
alteration of the T wave, myocardial infarction or LBBB, or loss of myocardial 
ventricular dyskinesias, or substance loss or evidence of coronary angiography 
and possible highlighted by stent or autopsy. 
In the field of cardiac surgery, in adult patients, the incidence of fatal cardiac arrest 
goes from 0.7 to 2.9%
16, 17
while the acute myocardial infarctions range from 2 to 
15%. In pediatrics, cardiac arrest is more frequent in patients with complex 
congenital heart disease perioperative (6%)
18
, mainly its common during cardiac 
catheterization (1%)
19
and is a frequent cause of death in the follow-up (22%) of 
deaths related to congenital heart disease 
20
. 
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1.3. Myocardial Ischemia; Ischemic heart diseases 
The main conditions under which patient may experience an ischemic infarction are 
Ischemic heart disease and Cardiopulmonary bypass (CPB). The term “Ischemic 
Heart Disease” (IHD) refers to a series of clinical pictures all share an underlying 
myocardial ischemia, generated spontaneously. Ischemic heart disease is still a 
major cause of death and disability worldwide, and it associates more healthcare 
costs compared to other chronic diseases. In the United States 13 million people are 
affected, out of them, more than 6 million suffering from angina pectoris, and more 
than 7 million have already had a MI. Although this disease is increasing in lower 
income classe. In both Europe and the United States, mortality was reduced by 
providing treatment, and by better control of risk factors regarding prevention. Men 
constitute 70% of all patients with angina pectoris, and an even greater percentage of 
them are younger than 50 years 
21
. 
The main risk factors include genetic predisposition, a high-calorie diet and high in 
fat, smoking and lack of physical activity, which together with high plasma levels of 
Low-Density Lipoprotein (LDL) cholesterol, low levels of High-Density 
Lipoproteins (HDL), hypertension, diabetes mellitus, age over 75 years, morbid 
obesity, peripheral myocardial ischemia and/or prior cerebrovascular disease and 
myocardial infarction, are all risk factors for coronary atherosclerosis. 
The atherosclerotic disease represents the overall main cause of heart disease, being 
able to determine a more or less marked degree of occlusion of coronary arteries 
(coronary artery disease) level
22
: its starting point is an alteration of endothelial 
functions including the regulation of vascular tone, retaining control of adhesion and 
diapedesis of inflammatory cells. When these functions are lost, it is inadequate to 
determine vasoconstriction, thrombus formation in the lumen and an abnormal 
interaction by the vascular endothelium activated with erythrocytes, platelets, and 
monocytes. These changes in endothelial defensive capabilities lead to the formation 
of atherosclerotic plaque as a result of the accumulation of fat subintimal smooth 
muscle cells, fibroblasts, and the intercellular matrix; these collections are 
distributed unevenly in different portions of the epicardial coronary circulation. 
The site of the obstruction influence clinical outcomes and their severity, so when it 
is borne by the main left coronary artery and proximal left anterior descending can 
be very dangerous for the patient's life. Very often, in the case of reductions in 
coronary patency, the creation of collateral circulation which may, at rest but not in 
the case of increased blood flow demand, to overcome the myocardial perfusion. 
Other pathological conditions such as vascular spasms (Angina Prinzmetal's 
variant), vasomotor physiological phenomena borne of a coronary artery stenosis, 
coronary arterial thrombi, emboli, abnormal vascular dilating capacity, impaired 
constrictions (microvascular angina), and far more rare in adult congenital 
anomalies, may also reduce coronary blood flow and myocardial perfusion. 
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In addition to inadequate adaptations of coronary blood flow, myocardial ischemia 
can also occur when oxygen demands are exceedingly increased. Obviously, this 
happens especially when coronary blood flow reduced, as in a left ventricular 
hypertrophy caused by aortic stenosis or hypertensive patient. An alteration in the 
transport capacity of oxygen by hemoglobin, for example under conditions of severe 
anaemia or carbon monoxide poisoning conditions, rarely can determine an ischemic 
event but can reduce the threshold level needed for moderate coronary obstruction 
manifests clinically. 
1.4. Extra Corporeal Circulation 
Extra Corporeal Circulation (ECC) is essential for cardiopulmonary bypass in the 
course of a cardiac surgery and Extra-Corporeal Membrane Oxygenation (ECMO) 
in the course of the Extra Corporeal Life Support (ECLS)
23
.  
In the course of ECC, a systemic inflammatory response develops, which contributes 
to the lung and kidney damage. Negative outcomes borne by these and other organs 
are supported by different mechanisms, such as surgical trauma, the hemodilution, 
endothelial damage induced by edema, ischemia-reperfusion injury borne by these 
organs and blood components. 
In the course of surgery with ECC, myocardial ischemic damage occurs can be 
divided into two main phases: an antecedent ischemia, as a result of a pre-existing 
coronary artery disease, hypotension or ventricular fibrillation; protected ischemia, 
which begins with the infusion of cardioplegia and connection of cardiopulmonary 
bypass. Reperfusion injury sustained during intermittent infusions of cardioplegia, 
after removal of the aortic clamp, or after discontinuation of cardiopulmonary 
bypass. Reperfusion injury may itself be divided into early (≤ 4 hours) and a late 
stage (from 4 to 6 hours). 
1.5. Physiology of myocardial perfusion 
At baseline, myocardial oxygen extraction almost maximum at rest and on average 
reaches about 75% of the arterial oxygen content 
3
, so any increase in the oxygen 
demands by cardiomyocytes can be satisfied only by a proportional increase in 
coronary blood flow and oxygen supply, viable firstly by vasodilatation of the 
coronary arterioles 
24
. In addition to the coronary blood flow, oxygen supply is 
determined directly from the arterial content of oxygen (PaO2): it is equal to the 
product of the haemoglobin concentration and arterial oxygen saturation, plus a 
small amount of oxygen dissolved in plasma. 
The basal requirement of myocardial oxygen is low (15%), and the cost of activation 
power is insignificant when the mechanical contraction ceases during diastolic 
shutdown (as in cardioplegia) and decreases during ischemia. The myocardial 
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oxygen demand is assessed clinically by multiplying heart rate-systolic pressure, 
resulting in the so-called "double" as myocardial contractility and wall stress cannot 
be measured in clinical practice. Normally the myocardium regulates the flow of 
oxygenated blood depending on the required variables in oxygen, to prevent any 
hypo perfusion of cardiomyocytes and subsequent ischemia to necrosis: a metabolic 
adjustment takes place in the course of physical activity or emotional distress, where 
the increased oxygen demands and energy substrates affect coronary vascular 
resistance; an autoregulation occurs instead of the physiological changes in blood 
pressure to maintain within a normal range the coronary flow. 
The main determinants of myocardial oxygen consumption (myocardial oxygen 
demand, MVO2) are essentially the heart rate, left ventricular contractility and the 
systolic pressure (or wall of the stressed myocardium). To meet the myocardial 
oxygen demands is in turn determined by appropriate respiratory function, levels of 
oxygen saturation, haemoglobin concentration by appropriate coronary 
circulation.The blood flow through the coronary arteries to the myocardium is 
influenced by the diameter and vascular tone, by the presence of collateral 
circulation, from the perfusion pressure determined by the pressure gradient between 
the aorta and coronary arteries and between arteries and capillaries endocardiac 
(being the direct flow from endocardium to epicardium), heart rate, which influences 
the duration of diastole in inverse proportion. Therefore, the heart rate is a 
determinant of both demand and supply of oxygen. 
1.5.1. Role of coronary circulation 
The blood flow in the coronary arteries is most represented during the filling phase 
and diastolic relaxation. The overall resistance of Coronary Vascular bed can vary 
considerably, with a concomitant change in the blood flow, myocardial demand, 
while draws a constant and high (70%) amount of oxygen from the blood. The 
coronary vascular resistance is primarily determined by the arterioles and 
intramyocardial capillaries, while large epicardial arteries are less influenced. The 
coronary vessels are the arteries so-called "functional end", meaning that there are 
anastomotic branches, but they are insufficient to establish a side circle functionally 
valid. Therefore, the area of coronary artery perfusion of a given place distal to the 
occlusion site represents the region at greater risk of MI.  When coronary blood flow 
is reduced significantly for a time ranging between 20 and 40 minutes, myocardial 
infarction begins to develop from the centre of the area at risk, from the sub 
endocardial layer, and then spread to subepicardial layers and at the edge of the area 
at risk with the passage of time. 
The evolution of myocardial infarction reflects the distribution of coronary blood 
flow pattern, stream most represented in the outer layers of the myocardium and the 
margins of the area at risk 
25, 26
. The evolution of myocardial infarction also depends 
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on the species concerned and the presence or absence of efficient collateral 
circulation: rodents such as have a high heart rate and tend to have a rapid evolution 
of myocardial necrosis
26
. 
Among the various aspects that can influence the development of myocardial 
infarction, in contrast to previous knowledge, the hemodynamic conditions of the 
subject seem to have a vital role; only the heart rate to some extent, can influence the 
progression of myocardial necrosis
27
. 
The primates possess few collateral circulations innate but are relatively resistant to 
ischemic myocardial infarction; there is not any MI for a time of coronary occlusion 
between 40 and 60 minutes, and even after the 90 minutes the size of the infarcted 
area still lower than for example in that of pigs. In humans even after a period of 
coronary occlusion between 4 and 6 hours, from 20% to 50% of the area at risk 
remains vital and therefore it can be retrieved through the reperfusion. The 
myocardium can be "saved" even after twelve hours of clinical onset, resulting in an 
improvement of the prognosis of the patient
28, 29
. It is unclear at the moment what is 
a mechanism in human‟s this ability to resist blood flow deprivation for so long, if 
the presence of well-developed collateral circulation at the time of the stroke, or an 
inherent resistance to ischemic damage, or if it reflects a preconditioning ischemia-
reperfusion due to previous episodes of ischemic reperfusion. Also, the use of 
medications such as beta-blockers, Inhibitors of Renin-angiotensin system, Statins or 
P2Y2 receptor antagonists, can provide a pre-existing cardioprotection and thereby 
reduce negative outcomes of myocardial ischemia-reperfusion injury
30
. 
1.6. Consequences of Myocardial Ischemia 
The consequences of inadequate myocardial perfusion affecting the metabolic, 
mechanical and electrical aspect of the heart: is to be altered contractile function of 
the myocardium, determining areas of hypokinesia or Akinesia (visible by 
echocardiography) more or less extensive or even in severe cases protrusions of the 
wall, thus leading to a significant impairment of myocardial pump function. Besides 
the above mentioned metabolic abnormalities, myocardial ischemia also determines 
electrical and mechanical alterations: as for the first it basically concerns the phase 
of Ventricular Repolarization, whose deterioration is visible to the 
electrocardiogram as reversal of the T wave and, when more severe, from elevation 
or ST segment depression, respectively if it is transmural necrosis or subendocardial 
infarction. Also, the ischemic myocardial damage leads to cardiac electrical 
instability that would result in possible isolated premature ventricular beats, 
tachycardia or atrial fibrillation. 
Most of the relative myocardial ischemia mortality and morbidity is still to be 
connected to the remodeling that follows the same; in fact, chronic systolic heart 
failure and an inappropriate remodeling of the left ventricle are crucial determinants 
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of morbidity and long-term clinical outcomes
31
. The cardiac remodeling is not to be 
considered solely as a late event in the post-MI but is closely related to the starting 
size of infarct associated with it. Therefore, an adequate remodeling following a 
severe ischemia-reperfusion can greatly improve patient outcomes
4
. 
The most typical and negative changes of left ventricle that occur after a myocardial 
infarction are represented by dilatation, hypertrophy, and change in spherical room: 
the hypertrophy is an initial compensatory mechanism that takes place in the remote 
area of myocardium not subject to MI, useful if limited in time, since a prolonged 
myocardial hypertrophy causes a concomitantly increase in the left ventricular mass. 
The adaptive process associated with long-term adverse clinical outcomes
32
. 
Another feature of left ventricular remodeling is ischemic myocardial interstitial 
fibrosis. From a biochemical point of view at the base of the left ventricular 
remodeling and its adverse effects, a fundamental role is played by the activation of 
Akt and Erk 1/2 that is in the long term, leads to deleterious hypertrophy of 
cardiomyocytes when the short term limits their apoptosis. Another of the most 
important markers of this counterproductive adaptation to the post myocardial 
infarction is the activation of a long-term neurohormonal response, in particular, the 
sympathetic nervous system and the Renin angiotensin aldosterone system: both the 
levels of aldosterone
33
 both of catecholamines are in fact useful predictors of 
cardiovascular mortality in patients post myocardial infarction
34
. 
1.6.1. Ischemia-related Metabolic Alterations 
The myocardial ischemia causes important alterations that usually occur in a 
temporal sequence defined "ischemic cascade," which first involves the metabolic 
aspect, then the mechanical and finally that of the myocardial electric cells. Unlike 
the hypoxia, where due to reduced availability of oxygen, can continue the 
production of glycolytic energy by anaerobic glycolysis. In ischemia, due to the 
reduced supply of oxygen and nutrients due to a reduced blood flow, it compromises 
the availability of substrates for Glycolysis. Under physiological conditions, the 
myocardium metabolizes fatty acids(60-90% of which constitute the total energy 
source), and glucose( 10-40% of total energy) by transforming them into carbon 
dioxide and water.  
The arrest of myocardial perfusion can be accidental when it takes place on the 
territory or iatrogenic to allow  intervention, quickly leads to the arrest of aerobic 
metabolism. The fatty acids cannot be oxidised so that, through anaerobic 
glycolysis, glucose is metabolized to lactic acid resulting in the release of free fatty 
acids causing arrhythmia and inhibits mitochondrial K-ATP channels, who can no 
longer maintain mitochondrial membrane potential, and glycogenolysis is gradually 
slowed and inhibited the increase in NADH and FADH2 and the drop in pH [8-10]. 
This is followed by the formation of lactates, a decrease in intracellular pH, the 
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progressive reduction of the high energy phosphates such as , as well as the 
accumulation of several catabolites, including those resulting from the pool of 
Adenine nucleotide.  The reduction of the reserves of ATP affects the ion exchange 
at the level of the sarcolemma, with increased Na
+ 
and K
+
 intracellular reduction due 
to its outflow, causing the onset of cardiomyocytes death.  
The increase in intracellular Na
+ 
results in an increase of intracellular calcium 
through an increased exchange of Na
+
 and Ca
2 +
. The reduced availability of ATP 
also lowers the intake of sarcoplasmic reticulum Ca
2 +
 and reduces the extrusion of 
Ca
2 +
 from the cell. The increase in intracellular Ca
2 +
 produces an overload of Ca
2 +
 
in mitochondria and that further decrease ATP production. Therefore Ca
2 + 
is playing 
a central role in the vicious cycle that leads to irreversible damage of the cell in case 
of persistent ischemia. If hypoxia continues, the aggravation of ATP depletion 
causes more damage: the cytoskeleton is dispersed, resulting in the disappearance of 
ultrastructural characteristics as microvilli and the formation of small protrusions on 
the cell surface. At this stage the mitochondria are swollen to an inability to control 
their volume, the endothelial pattern remains dilated, and the whole cell becomes 
particularly voluminous, with increased water content and the concentration of 
sodium and potassium chlorides. Due to the high dependence of myocardial function 
by oxygen, severe ischemia induces loss of contractility within 60 seconds. This can 
lead to acute heart failure even before myocardial necrosis occurs. If the availability 
of oxygen is restored, all these changes are reversible; On the contrary, if ischemia 
persists, it reaches to irreversible damage and necrosis. 
A myocardial ultrastructural alterations, cellular and mitochondrial swelling, 
glycogen depletion are potentially reversible. While severe ischemia lasting for at 
least 20-30 minutes leads to irreversible damage, with necrosis of cardiomyocytes. 
The ultrastructural evidence of irreversible myocardial damage occurs only after a 
serious and prolonged myocardial ischemia. A key characteristic of the initial phases 
of myocardial necrosis is the loss of the integrity of sarcoplasmic membrane, which 
allows the intracellular molecules moves to cardiac interstitium and then into the 
circulation. Necrosis is typically complete within 6 hours after the onset of severe 
myocardial ischemia.  From the morphological point of view, the irreversible 
myocardial damage is associated with a serious mitochondrial swelling, an extensive 
cytoplasmic membrane damage with the appearance of myelin figures, and a bulge 
of lysosomes. In mitochondrial matrix, large dense bodies and amorphous develops. 
In the myocardium, these elements confirms to the irreversibility of the lesions and 
can be observed after 30-40 minutes of ischemia. 
A fatal injury begins to be determined after 20 minutes of the coronary blood flow 
occulusion, and myocardial exclusion progresses as a wavefront from 
subendocardial to avoid the epicardium. After 60 minutes, the third most internal 
wall is irreversibly damaged. After 3 hours it remains only a fabric edge 
subepicardial, and the trans mural infarct extension is complete after 3-6 hours of 
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occlusion 
35
. Instead, the entire experimental subendocardial infarction undergoes 
irreversible damage within an hour of the occlusion, and myocardial necrosis 
progression is 4-6 hours after widely by coronary occlusion. The apoptosis of 
cardiomyocytes has been identified as a fundamental process of all stages of 
myocardial infarction, suggesting that it might be largely responsible for the death of 
cardiomyocytes during the acute phase of myocardial ischemia, as well as the 
progressive loss of cells survived during the first subacute and chronic stages
36
. 
Apoptosis also seems to play a significant role in the deterioration of left ventricular 
function in ischemic regions 
37
. 
This may suggest that the inhibition of apoptosis may limit the loss of 
cardiomyocytes induced by ischemia, particularly in chronic ischemic myocardium 
reducing left ventricular remodeling and improving the prognosis. The way of 
apoptosis is primarily triggered by the liberation of proapoptotic molecules from 
damaged mitochondria, called intrinsic or mitochondrial pathway. The latter is the 
result of increased mitochondrial permeability and release proapoptotic molecule 
within the cytoplasm. The release of mitochondrial proteins in the cytoplasm break 
the delicate balance between pro-and anti-apoptotic members of the BCL family. 
During normal conditions, anti-apoptotic proteins reside in the cytoplasm and in the 
mitochondrial membranes where they control the mitochondrial permeability and 
prevent the leakage of mitochondrial proteins.  
The anti-apoptotic Bcl-2 and BCL-X factors are antagonized by the pro-apoptotic 
proteins. The combination of these events leads ultimately to the release of 
cytochrome into the cytoplasm; a mitochondrial protein can trigger, along with other 
within a structure called the apoptosome, caspase 9, the initiator of the 
mitochondrial pathway. A group of cysteine aspartate protease, which in normal 
cells reside in the cytosol as inactive form (pro-caspases). This terminates at the 
final phase of apoptosis, also common to the intrinsic pathway activation, 
characterized by activation of effector caspases, which ultimately determine the 
characteristic DNA cleavage, fragmentation of the nucleus and lyses of myofibrils. 
Apoptotic cells and their fragments are then recognized by different receptors on 
macrophages and finally swallowed. In the ischemic heart then we witness an 
alternative activation and inactivation of multiple genes and their products. 
Among the events resulting from myocardial ischemia are found metabolic acidosis, 
reduced production of Adenosine Tri-Phosphate (ATP), the loss of sodium-
potassium ATPase pump, as well as the release of chemicals that stimulate chemo-
and mechanoreceptors innervated by non-myelinated nerve cells in the structure of 
cardiomyocytes and around the coronary arteries
38
. Among the substances which are 
released there are lactate, serotonin, oxygen free radicals and adenosine
39, 40
; in 
addition to these there are others, such as serotonin, 5-hydroxytryptamine, 
thromboxane A2 coming from platelets that are frequently found aggregated in 
correspondence at the coronary obstruction, which may be partly responsible for 
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myocardial ischemia and angina 
41, 42
. In the ischemic heart there is the considerable 
production of Reactive Oxygen Species (ROS), or oxygen molecules with an excess 
of electrons that make it chemically very reactive: ROS, using the phenomena of 
lipid cell membrane constituents, can damage of cardiomyocytes and thus contribute 
to ischemic damage.  
1.6.2. Myocardial Stunning and hibernation 
The extent and nature of myocardial damage depend largely on how long and how 
much has been reduced coronary blood flow 
43, 44
. In fact, a cessation of coronary 
blood flow lasting less than 20 minutes results in a reversible damage represented by 
the contractile dysfunction associated with a complete although slow recovery after 
myocardial reperfusion a phenomenon referred to as "myocardial stunning" 
45, 46
. 
The mechanism underlying this prolonged contractile dysfunction comprises firstly 
an increased production of reactive oxygen species, which occurs early during 
reperfusion 
47
, and an alteration of coupling between excitation and contraction of 
cardiomyocytes due to oxidative modification of Sarcoplasmic reticulum and 
contractile proteins. Another phenomenon which follows repeated brief episodes of 
coronary artery occlusion or to the reduction of moderate coronary blood flow but 
more prolonged is the so-called "hybernating myocardium" which consists of a 
reduced contractile function of the myocardium which remains vital and subject to a 
possible recovery following the reperfusion(Fig. 1.1). The hibernating myocardium 
presents both aspects of the damage, such as loss of contractile proteins, fibrosis and 
abnormal donut-shaped mitochondria, both signs of adaptation which has met, such 
as altered expression of mitochondrial proteins, and proteins related to 
cardioprotection 
48, 49
. 
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Figure 0.1. Myocardial Ischemia may present as reversible myocardial dysfunction in 
association with reversible electrocardiographic changes and angina pectoris. Additional 
consequences of myocardial ischemia include: (1) myocardial infarction with permanent 
contractile dysfunction caused by severe long lasting ischemia, (2) hibernating myocardium 
as a result of chronic hypoperfusion, (3) stunned myocardium after reperfusion of ischemic 
myocardial tissue; and (4) preconditioned myocardium after brief ischemic insults. The 
preconditioned myocardium may in turn offer protection during a subsequent ischemic bout 
and has been demonstrated to reduce infarct size in animal models. It is not clear at present 
weather the preconditioned myocardium is capable of having the recovery of stunned 
myocardium. Adapted from (Margreeth B et. Al. 1996)
50
. 
 
1.7. Treatment option of myocardial ischemia 
Although a timely reperfusion of the myocardium at risk represents the most 
effective way to restore homeostasis of myocardial cell, it is also important to 
maintain an optimal balance between supply and demands of oxygen, so as to save 
the widest possible area of myocardium at risk around the areas most damaged by 
ischemia. The progression of irreversible damage is in fact accelerated by factors 
that increase myocardial oxygen consumption as tachycardia or reduce its 
contribution as in arterial hypotension. Potential mechanisms and measures to 
counteract the lack of oxygen at myocardial cells include firstly the reduction of 
myocardial oxygen consumption: this will lead to a prolonged survival by saving 
energy on the part of the myocardial cells and to a reduction in the catabolites 
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production.Since your heart rate is the main determining factor in myocardial 
consumption of oxygen (which is halved with halving the number of heartbeats), its 
reduction is a crucial mode of protection from myocardial ischemia
51
by keeping the 
patient at rest, possibly using a light sedation and through the use of beta-blockers 
medications, which reduce the myocardial work, also reducing blood pressure (after 
load) and contractility. 
Although there are not always unique data about the deleterious effects of Free Fatty 
Acids ( FFA)
52
 is considered. It is believed that this metabolic pathway in ischemic 
conditions presents several disadvantages to the myocardial cells. Indeed, in addition 
to a higher oxygen consumption, also involves the inhibition of glucose oxidation 
and an increase in the production of lactate and protons, which further depresses 
myocardial function in ischemic areas. Furthermore, the FFA alter cellular ionic 
homeostasis leading to an increase of arrhythmic substrate. Therefore, therapeutic 
interventions to partially inhibit the uptake and oxidation of FFA and to promote the 
use of glucose utilization during ischemia should have favorable effects on 
myocardial cells 
53
.  
It has been long used a solution of Glucose-Insulin-Potassium (GIK) with the aim of 
increasing Glycolysis and reduce the uptake of FFA and metabolism of myocardial 
cells during Acute Myocardial Infraction (AMI), and even the administration of 
insulin alone was proposed with a similar goal. The effects of GIK solution (or 
insulin alone) in preserving the integrity of cardiomyocytes in this context, however, 
remain controversial. In fact, some studies  have shown favourable effects on 
survival with this approach, both in diabetic patients and in non-diabetics, but other 
studies have failed to confirm these findings
53
. 
1.7.1. Pre and Post conditioning  
The 2-5 minute typically transient ischemia, it becomes metabolically more resistant 
to any possible subsequent more prolonged ischemia; this phenomenon is called 
ischemic preconditioning. It provides protection against ischemia occurring in 2 
hours after transient ischemic preconditioning (early preconditioning), but also 
against a late-occurring after 24 hours and ischemia for up to 72 hours after the 
episode of ischemic preconditioning (delayed or chronic preconditioning) 
54
. This 
reduces the size of myocardial necrosis by reducing the infarcted area of 40-75%and 
protects the heart from ischemia-induced damage. A key role is carried out in 
particular by the Protein Kinase C (PKC), and specifically its isoform PKCε, it 
seems like a central mediator of the IPC (Fig. 1.2). In fact, various substances that 
accumulate in the interstitium during myocardial ischemia and that are involved in 
the IPC have in common the ability to activate PKC through the activation of 
Phospholipase C (such as bradykinin, adenosine, norepinephrine, opioid) 
55, 56
or 
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through other routes, such as the activation of protein kinase G (as in the case of 
nitric oxide) 
57
. 
 
Figure 0.2 The graphical representation of ischemia reperfusion injury and 
cardioprotection by pre- and postconditioning (adapted from Ferdinandy P. et al. 2007)
58
. 
 
The key event finals of the IPC, resulting in the activation of PKC, seems to be the 
opening of ATP-sensitive potassium channels (KATP channels) and the cytoplasmic 
membrane of mitochondria is opening which is mediated by phosphorylation of 
proteins channel by precisely PKC and that causes a reduction of the calcium influx 
and cellular energy expenditure. The IPC can be blocked by glibenclamide an 
antagonist of K-ATP channels
59
. 
The formation of low amounts of ROS after the brief period of ischemia, although 
insufficient to cause cellular damage, may be able to activate cellular mechanisms 
involved in the Cardioprotection. Low concentrations of ROS seems to activate 
certain enzymatic pathways involved in IPC (Guanylate Cyclase, cyclooxygenase, 
tissue factor, tyrosine) 
60
. Moreover, some substances capable of generating ROS 
(acetylcholine, bradykinin, opioids, anaesthetics) are also known as preconditioning 
reagents
61
. 
Finally, recent data suggest that preconditioning effect against ischemic myocardial 
damage can be achieved by transient episodes of ischemia induced in other areas of 
the body (for example, lower limbs)
62
, a phenomenon termed remote 
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preconditioning.A final protective mechanism, the post-conditioning myocardial 
infarction, is the ability to provide pharmacological agonists administered by 
throwing an intermittent ischemia or heart at the time of reperfusion; this protection 
mechanism by myocardial ischemic injury has the greatest potential to influence the 
irreversible damage because it can be induced after myocardial ischemia is 
established, rather than requiring pre-treatment
63
. 
1.7.2. Reperfusion 
The dependence of myocardial recovery from treatment time applies particularly to 
the patients treated with fibrinolysis or PCI
64
. This time dependence can be 
especially critical for fibrinolysis due to decreased efficacy of fibrinolytic drugs with 
the progressive organization of coronary thrombi over time. The study conducted by 
De Luca et al.
64
 demonstrated how every minute of delay at the beginning of the 
treatment, such as performing a primary angioplasty, engrave on mortality to one 
year, even after considering the basic conditions of the patient more precisely it has 
been seen as the one-year mortality risk is increased by 7.5% for every 30 minutes 
of delay in initiation of treatment(Fig. 1.3).  
The cornerstone of myocardial ischemia treatment consists of procedures enabling a 
rapid restoration of coronary blood flow in the area of ischemic myocardium
65
. This 
is a concept not older than 40 years reported by Ross and Associates
66, 67
 who first 
said that 180 minutes of reperfusion after coronary occlusion reduces the infarct size 
in dogs. These findings were quickly transferred to patients suffering from acute 
myocardial infarction who underwent Percutaneous Coronary Intervention (PCI) or 
thrombolysis to restore blood flow to the myocardium
44, 68
. 
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Figure 0.3. Mediators in myocardial reperfusion injury Reperfusion injury results from 
several complex and interdependent mechanisms that involve the production of ROS, 
alterations in intracellular calcium handling, microvascular and endothelial cell 
dysfunction, altered myocardial metabolism, and activation of neutrophils and platelets. 
Reperfusion injury is manifested as stunned myocardium, reversible microvascular injury, 
and lethal myocyte necrosis(adapted from M. Zubrzycki et al. 2013). 
The prevention of cell death by restoring blood flow depends on the severity and 
duration of pre-existing ischemia.  When more rapidly blood flow is restored, the 
greater will be the recovery of left ventricular systolic function improving diastolic 
function and the reduction in overall mortality.  
The benefits of coronary reperfusion were already established, Krug et al. 
69
 and 
then Kloner et al. 
70
 showed the drawback in their studies conducted on dogs, the so-
called "coronary no-reflow phenomenon", which is the absence of reperfusion of the 
ischemic area with terminal coronary occlusion. According to these studies, while 
after 40 minutes, long enough to cause irreversible damage to most cardiomyocytes, 
you are to determine little or no change in the pattern of perfusion of large areas of 
previously ischemic tissue. After 90 minutes of transient ischemia following instead 
of a reduced or absent perfusion of large areas of ischemic tissue. The no-reflow 
phenomenon 
71
is found in approximately 35% of patients undergoing reperfusion 
treatments, and its incidence increases with increasing delay in the start of 
reperfusion and is associated with a poor prognosis in patients with acute myocardial 
infarction undergoing reperfusion therapy 
72
.  Also to note how the Interventional or 
surgical revascularization may actually, in turn  induce a myocardial infarction 
collateral to the same procedure. 
Despite considerable improvements in cardioprotection intraoperative cardioplegic 
arrest (cessation transient contractile activity of the heart, produced by infusion in 
 36 
 
 
coronary circulation hypothermic conditions solutions based on potassium chloride), 
which allows you heart surgery while protecting the muscle from ischemic damage 
due to the interruption of blood flow in the coronary arteries, hypothermia and many 
more advanced surgical techniques. It is not always possible to use surgical 
reperfusion through CABG promptly. Although primary angioplasty compared with 
thrombolysis is able to get a higher rate of reperfusion in patients "late" with respect 
to the appropriate time to attack the coronary occlusion, it cannot avoid or prevent 
the same myocardial necrosis, which is closely related to the duration of the 
occlusion especially in high-risk patients
73, 74
. The size of infarcted area turns out to 
be the main determinant of the long-term mortality of chronic heart failure, and 
therefore, the ability to limit the extent of the myocardial damage remains one of the 
main objectives
44
. 
1.8. Ischemia Reperfusion Injury 
Although the primary purpose is the timely restoration of coronary blood flow to get 
a reduction in the infarct size and an improvement in ventricular function, the same 
reperfusion may result in tissue damage, lethal and a series of cellular events that are 
defined as "myocardial ischemia-reperfusion damage"
75
. Among the first 
experimental studies by Reimer et al.
25
, 
26
  demonstrated in numerous studies 
conducted on dogs, as the sign of irreversible myocardial damage such as rupture of 
the sarcolemma were particularly evident during reperfusion; at that time still we did 
not know clearly if the irreversible damage caused to the myocardium was 
attributable to reperfusion or if only became more manifest with it(Fig. 1.4). So, it 
opened new debate about the identity of this lethal reperfusion myocardial damage
76
, 
after a long debate finally an epilogue found by  Vinten-Johansen et al.
77
, in which 
he identified the so-called "ischemic post conditioning phenomenon" repeated 
episodes of coronary occlusion during early reperfusion proved to be able to reduce 
the size of infarcted area in dogs. This discovery was later confirmed in patients with 
acute myocardial infarction undergoing coronary reperfusion
78
. These studies once 
again emphasized what had already been partially mentioned in previous studies on 
reperfusion, or that modified reperfusion procedures were able to attenuate the 
myocardial damage otherwise irreversible 
79
, reducing the signs of damage at both 
morphological and functional level 
80
. 
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Figure 0.4. Major mediator of lethal reperfusion injury. Ischemia-reperfusion injury in the 
heart. Cellular changes during reperfusion of myocardium include mitochondrial re-
energization, generation of ROS, intracellular Ca2+ overload, rapid restoration of 
physiologic pH, and inflammation, which all contribute to cardiomyocyte death via an 
opening of the mitochondrial permeability transition pore.(adapted from Ernest Levy 2010). 
1.8.1.Oxygen free Radicals 
A key role in ischemia-reperfusion injury is done by the release of reactive oxygen 
species
81, 82
.  While during ischemia increases there is an increase of purines derived 
from the catabolism of ATP. The conversion of Xanthine dehydrogenase in 
Xanthine oxidase by Ca
2 +
, enzyme which converts Xanthine to uric acid, during 
reperfusion the oxygen supply enables to Xanthine oxidase to form uric acid from 
purine accumulated as a byproduct of the reaction produce reactive oxygen species. 
Reactive Oxygen Species (ROS) such as the superoxide anion (O
-
2), the hydrogen 
peroxide(H2O2)and the hydroxyl radical(OH), play a key role in both mitochondrial 
and cytosolic levels as well as for normal functions of the mitochondria. An 
imbalance between production and removal of free oxygen radicals results in so-
called "oxidative stress", involved in various pathological conditions as well as in 
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determining macromolecular damage
83
. In the evolution of damage by inducing 
endothelial cell surface alterations occur adhesion and activation of circulating 
neutrophils. The neutrophils release ROS and hydrolytic enzymes that damage cells 
in ischemia. The ischemia-reperfusion also activates the enzyme Nitric Oxide 
Synthase (NOS), which leads to the production of Nitric Oxide (NO) which reacts 
with the ROS forming toxic reactive species (peroxynitrite). Reactive oxygen 
species generated during reperfusion phase by various oxidative reactions, involving 
among other are, the NADPH oxidase and myeloperoxidase leukocyte
84
, 
participating in the endothelial dysfunction and subsequent altered vasomotor 
capacity of coronary artery
85
.  
In addition to these actions, reactive oxygen species can produce deleterious effects 
on myocardial cells resulting in a structural and enzymatic proteins and lipid 
peroxidation of cell membranes. Their importance in reperfusion injury is suggested 
by experimental studies that showed the ability of treatment with antioxidants, such 
as superoxide dismutase, to improve cardiac function in ischemia-reperfusion 
86
. 
However, it lacks the evidence that antioxidant treatment improves myocardial 
damage associated with reperfusion in humans and some study has not been able to 
confirm the induction of irreversible damage by free radicals in patients undergoing 
cardioplegic arrest and reperfusion during coronary artery bypass graft surgery 
87
. 
In some pathological conditions, the overproduction of reactive oxygen species 
(ROS) can be stimulated by an overload of calcium (Ca
2 +
), in spite of calcium itself 
has numerous positive functions at the mitochondrial level 
81
. This malicious 
calcium overload can be determined by the loss of adenosine triphosphate (ATP), 
loss in turn determined by an altered function of the Na
+
 /Ca
2+  
exchanger.  
1.8.2. Inflammation and activation of complement system 
The inflammatory damage in the reperfusion is primarily determined by a massive 
circulating neutrophils invoked in the reperfused area by cytokines and adhesive 
molecules expressed by endothelial and parenchymal cells. Above all release by the 
cytosolic components from necrotic cells. This inflammation causes, in turn, further 
tissue damage. The damage triggered by reperfusion is primarily associated with the 
release of several inflammatory molecules such as cytokines including  IL-1β, IL-6, 
IL-8, IL-10, complement activation, the release of polymorphonuclear leukocytes as 
well as its actual cellular damage
88, 89
. 
To demonstrate a state of inflammation in the blood boosted survivors following a 
cardiac arrest reveals a level of IL-6 twenty times higher than patients who 
survived
90
, or about fifty times exceeding the levels under physiological 
conditions
91
. This state of inflammation triggers very quickly as soon as coronary 
blood flow is re-established 
92, 93
.The extent of the damage at the cellular level 
depends on some factors, including the duration of absence blood flow level 
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particularly in myocardial tissues, the degree of response to the more or less optimal 
treatment as well as the probability of individual patient survival 
94
. 
To emphasize how many patients with early hemodynamic dysfunction following a 
cardiopulmonary resuscitation for cardiac arrest have favorable neurological 
outcome
95
, therefore the number of patients who escapes the clinical outcomes 
associated with ischemia-reperfusion injury could be significantly reduced by all 
those treatments to reduce premature mortality and damage associated with 
inflammation and trauma present in the chain of ischemia-reperfusion events. The 
IL-6 , TNF-α and endothelin that cause vasoconstriction, increasing the adhesion of 
neutrophils and platelets to endothelium, chemotaxis of neutrophils, and effects with 
systemic abnormalities of vascular function. Although, the complement system is 
capable of contributing to ischemia-reperfusion injury
96
: some IgM antibodies for 
unknown reasons tend to be deposited in ischemic tissues; when blood flow is 
restored, the complement fractions bind to these antibodies are activated and induce 
a further cellular damage and increased inflammatory reaction
97
. 
1.8.3. Increased permeability of mPTP 
Under hypoxic conditions, cellular metabolism switches from a state to an oxidative 
glycolytic state, the pH is reduced leading to a state of acidosis, and Na
+
/H
+ 
 
exchanger  tries to re-establish a physiological cellular pH. The sodium gradient thus 
increased driving the counter current by Na
+
/Ca
2 +   
 exchange, but the latter cannot 
act same, because the lack of ATP prevents their activation. Consequently, it is to 
determine an excess which eventually leads both to an overproduction of reactive 
oxygen species and the opening of the mPTP. Specifically, overstressing of calcium 
induced by calcium, combined with certain pathological conditions, results in a 
persistent state of the opening of these mitochondrial pores.  Due to this ischemic 
tissue, the pathological condition characterized by a reduced value for Adenosine 
Mono-Phosphate/Adenosine Tri-Phosphate (ATP/AMP) and the depletion of 
adenylic nucleotides.  
Once the mPTP opens, mitochondrial membrane potential is no longer maintained, 
leading to a major influx of water, mitochondrial swelling and rupture
81
. 
Specifically, the opening of mitochondrial transition pore determines a cell 
membrane depolarization and a bulge in the array. This in turn, leads to the outer 
mitochondrial membrane rupture and release of proteins such as cytochrome C from 
intermembranous space to the cytosol. The latter cellular event plays an important 
role in cell death both in neuronal and myocardial level
98, 99
. 
The continuing opening of mPTP not only makes the mitochondrion unable to 
produce ATP through oxidative phosphorylation but also determines the breakdown 
of ATP molecules produced through glycolysis in an attempt to restore the 
physiological cellular pH and concentration gradient normally present across the 
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mitochondrial membrane. During prolonged periods of ischemia that determine 
acidosis exerts an inhibition on the mitochondrial transition pore preventing you 
from opening; Once blood flow is restored and re-established adequate partial 
oxygen tension, the cell reverts to aerobic metabolism and the physiological pH 
increases, resulting in the opening of mPTP and an increased release of reactive 
oxygen species. Although as just seen low pH levels can inhibit the opening of 
mPTP, normalizing pH alone cannot prevent tissue damage that ensues. 
Nevertheless, it is still important for the purpose of inhibiting the opening of these 
mitochondrial pores and ultimately reduces ischemia-reperfusion injury, maintain 
proper mitochondrial function and prevent pathological conditions predisposing 
tissue damage related to mitochondria. 
1.8.4. Role of mitochondrial DNA 
During the development of ischemia-reperfusion injury following the rupture of 
mitochondria, mitochondrial DNA is released. Just considering this process, 
mitochondrial DNA has been recently evaluated as a possible marker of myocardial 
infarction
100, 101
.  In fact, in addition to apoptosis induced by the rupture of 
mitochondria, the same circulating mitochondrial DNA seems to be able to 
contribute to the death of cardiomyocytes 
101
. 
When it increase a tissue damage, mitochondrial DNA that is released into the 
circulation as a result of disruption of mitochondria is recognised by TLR9 as 
foreign material, as very similar to bacterial DNA, as a result, the body develops a 
systemic inflammatory response
102
. In support of this, recent clinical studies have 
used the increased circulating levels of mitochondrial DNA and overexpression of 
TLR9 as predictors of mortality in patients hospitalised in ICU 
103
. Furthermore, 
urinary mitochondrial DNA has been used as a marker of mitochondrial dysfunction 
in acute kidney injury 
104
.  Thus circulating mitochondrial DNA could constitute an 
important means for evaluating myocardial damage, specifically in the transplant 
ischemia induced by the sequence of events and reperfusion. 
In a recent study of  CABG, an intervention that  temporarily blocks blood flow to 
the myocardium, was seen as being induced the release of massive amounts of 
mitochondrial DNA free in the circulation
105
 strengthens the hypothesis that this 
same DNA, can be used as marker of ischemia-reperfusion injury. 
1.8.5. Myocardial Cellular Death 
Ischemia-reperfusion may cause different forms of cell death, such as programmed 
cell death, necrosis and apoptosis. In mammalian cells, there are two most important 
pathways in the activation of the apoptotic cascade, although there are other lesser 
known pathways: intrinsic and extrinsic. The "intrinsic" is triggered by 
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ischemia/reperfusion, hypoxia and oxidative stress, and is mediated by the damaged 
mitochondria, which releases substances that activate the caspases cascade and 
translocation in the nucleus where they induce, directly and indirectly, DNA 
fragmentation. 
1.9. Myocardial Protection related to Ischemia-Reperfusion Injury 
In recent decades, numerous studies have shown that the myocardial cells possess 
several coping mechanisms that aim to limit the damage of ischemia/reperfusion. 
The cellular mechanisms underlying certain phenomena of myocardial cell 
protection from ischemia/reperfusion (as the pre and post conditioning) remain to be 
clarified in an appropriate way, but they are likely to be numerous. It remains to be 
proven whether pharmacological interventions can improve myocardial cellular 
metabolism towards a more efficient use of oxygen and energy stocks can help 
protect the myocardium under ischemic conditions. Also, the option of using drugs 
to mimic the phenomenon of preconditioning or Post conditioning in vivo 
application of ischemic episodes post conditioning and the ability to prevent, with 
pharmacological, cell death by apoptosis, are other fascinating possibilities still 
developing security assessment. 
It should also be noted that other possible treatment options proposed to prevent the 
reperfusion injury based on the physiopathological basis (including Na+/H+ 
exchanger inhibitors, regional hypothermia, Anti-inflammatory and reperfusion 
gradual), none has been tested successfully in patients with AMI. 
1.9.1. Anti-apoptosis 
Inhibition of apoptosis can limit the loss of myocardial cells induced by 
programmed cell death. It has been shown how different drugs known to have 
favourable effects in ischemic cardiomyopathy, including angiotensin converting 
enzyme inhibitors, Angiotensin II antagonists and beta blockers, have anti-apoptotic 
effects in animal models, through inhibition of the Renin-angiotensin system and 
sympathetic nervous system effectors that, under certain conditions can trigger 
apoptosis 
106
. Antioxidant agents can act as anti-apoptotic substances, because 
oxidative stress and the generation of ROS may trigger the "intrinsic" apoptosis. In a 
mouse model of ischemia-reperfusion, in fact, the antioxidant was able to prevent 
the over-expression of various pro-apoptotic molecules 
107
. Specific target potential 
to prevent apoptosis include caspases and endonuclease. Inhibitors of these enzymes 
are capable of reducing infarct and left ventricular remodelling in experimental 
models of ischemia-reperfusion damage 
107
. 
Finally, the insulin-like growth factor can improve heart function in animal models 
of cardiomyopathy through an anti-apoptotic effect mediated by inhibition of 
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Caspase-3. However, they cannot be overlooked some boosts in application limits of 
therapeutic strategies aimed at inhibiting the apoptosis in clinical practice, especially 
about the carcinogenic potential of such intervention. Furthermore, while in animal 
models the time and doses of anti-apoptotic drugs are well controlled, there is no 
well defined by referring to their application in clinical practice.  
1.9.2. Mechanical Assistance  
Among the mechanical assistance systems that can be used in conditions of 
myocardial ischemia,  infarction and post cardiac arrest is Extracorporeal Membrane 
Oxygenator (ECMO). It is a closed loop system that replaces the heart and lungs of 
the patient when these are not able to perform its task, providing a valid 
cardiopulmonary support when this is necessary for an extended period and allowing 
a functional recovery of heart and lungs.  It has no therapeutic action, but allows you 
to implement a medical treatment which would exclude from the cardiac and 
pulmonary functionality. 
There are mainly two types of Veno-Arterial (VA) ECMO: and Continuous Veno-
Venous (VV)(Fig.1.5). And both types provide respiratory support, but only that 
hemodynamic support VA also provides a cardio-circulatory function. 
 
Figure 0.5. Peripheral venou-arterial ECMO cannulation approach femoral vein (for 
drainage), (A) femoral, (B) axillary, (C) carotid, artery are used for perfusion. ECMO, 
Extra Corporeal Membrane Oxygenation.(Adapted from George Makdisi 2015)
108
 
In the first type, the blood is drained from the venous access is then conveyed to the 
arterial access, while in the second case the blood is drained and re-infused directly 
in vein. When the patient is connected to the ECMO, blood is taken from the 
patient's cardiovascular system through a cannula, conveyed towards the membrane 
oxygenator tanks to pressure exerted by the centrifugal pump. The later gives to the 
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blood a circular motion, and convey it in a vortex that, creating a vacuum allows the 
recall of blood from the patient and on the other hand a kinetic energy that pushes 
the blood through the spiral towards the membrane oxygenator. 
The pump then generates the flow, and the number of turns determines the share of 
ejection fraction and, therefore, the scope of the system. The pump types that are 
generally used are centrifugal pumps and magnetic levitation pumps. The flow that 
is produced is one of the linear types, and not pulsed. At the level of the output line 
from the centrifugal pump is positioned a flow detector. The Oxygenator consists of 
a continuous membrane, consisting of hollow fibers, in which the mixture of air and 
oxygen flows countercurrent to the blood, which flows perpendicularly to it; It 
creates a wide exchange surface between air and blood with a minimum thickness, 
the diffusion exchange of oxygen and carbon dioxide. The oxygenation is 
determined by the flow rate, while the elimination of carbon dioxide can be 
controlled by adjusting the speed of the flow upstream within the oxygenator. There 
is also a controller of the spray, which can change the flow rate of the mixture and 
the oxygen fraction in the mixture itself. The heat exchanger maintains a 
physiological body temperature or relatively hypothermic; this is necessary because 
the continuous passage of the entire cardiac output through the pipes, pumps and 
oxygenator positioned outside the patient determines a rapid heat loss resulting in 
hypothermia. 
Before making the connection with the ECMO and during use, the patient should be 
on anti-coagulation, usually with unfractionated heparin, and then proceeds with the 
cannulation and connection to the circuit of ECMO. Heparinized coating has been 
developed for various circuit components, so as to reduce the inflammatory response 
that coagulation associated with extracorporeal circulation. 
109
. The Cannulation can 
be performed using various techniques, surgical or percutaneous: when you need a 
cardiopulmonary resuscitation, straws can be positioned with percutaneous 
technique Seldinger technique to accelerate the procedure. Otherwise, they prefer to 
implement a surgical isolation of the vessels. Cannulation can also be central or 
peripheral
110
. 
Following a cardiac surgery, the site of cannulation "Central", aorta and right atrium, 
used for cardiopulmonary bypass, translates to "serial" jugular femoral-femoral. 
Alternatively the same cannula can be detached from the cardiopulmonary bypass 
machine and connect to the circuit of ECMO.  
Cannulation can be central or peripheral blood that can be made to the common 
femoral artery, axillary artery or common carotid artery, while the venous cannula is 
placed at the level of the common femoral vein or internal jugular vein; 
subsequently, the cannula correctly positioned, are fixed with wire stitches to the 
patient's skin
111
. Specifically, in VV ECMO the venous cannula are usually placed to 
the left or right common femoral vein to drain and the right internal jugular vein for 
the infusion. The VA ECMO a venous cannula is placed in the inferior vena cava or 
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right atrium, and an arterial cannula is positioned in the right femoral artery. 
Occasionally the femoral vessels may not be available to cannulate the ECMO; in 
those cases, we can use the left common carotid artery or subclavian artery
112
. 
After cannulation, the patient is connected to the ECMO circuit, and the blood flow 
is increased to obtain satisfactory hemodynamic and respiratory parameters. 
Assuming the brain function of a post-cardiac arrest patient is reduced minimally or 
not assessable, ECMO VA can provide a valid cardiopulmonary support: in these 
cases the device is used until the patient can recover independently or otherwise 
prior to implantation of a Ventricular assist device, or LVAD can be used as a bridge 
therapy to cardiac transplantation. 
Among the indications for the use of ECMO themselves, in addition to cardiac 
arrest, even the heart failure secondary to myocardial infarction, the refractory 
cardiogenic shock, the impossibility to weaning from cardiopulmonary bypass 
following cardiac surgery, and as an aid in conventional cardiopulmonary 
resuscitation
113
. In two observational studies, the use of ECMO in patients with 
cardiac arrest has been associated with an increased survival compared to single 
conventional cardiopulmonary resuscitation
114, 115
. 
The only absolute contraindication to the use of ECMO is a pre-existing condition of 
severe neurological damage or impossible recovery, such as a severe neurological 
impairment or end-stage cancer. Relative contraindications, which must be assessed 
on a case by case basis include uncontrollable bleeding and patients with a poor 
prognosis very strict criteria need to initiate.  The main complications related to the 
use of ECMO system includes bleeding, the most common complication, due to the 
extended period of coagulation, Thrombo-embolic complications, infrequent but can 
be devastating, especially in ECMO VA; these complications can be prevented by 
maintaining an adequate anticoagulation and observing the circuit looking for signs 
of a blood clot  forming Neurological damage, Heparin-induced thrombocytopenia 
and platelet transfusion becomes necessary, Systemic inflammation, Multi-Organ 
Failure (MOF). 
The consumption of coagulation factors and thrombocytopenia often needed blood 
transfusions, which can cause adverse reactions and secondary damage to the lungs. 
Systemic inflammation contributes to various clinical outcomes, including kidney, 
heart and lung damage
116
.  Among the main mechanisms underlying includes 
surgical trauma, the hemodilution, endothelial damage induced by oedema, the 
damage from ischemia-reperfusion injury of various organs, the contact activation of 
blood components during extracorporeal circulation
117
. In determining the leukocyte 
activation and systemic inflammation, it was recently demonstrated in an 
experimental model of extracorporeal circulation, like the oxygenator has a role in 
this 
118
. Due to these numerous side effects on hemodynamic support with ECMO 
can be maintained only for short periods and should be removed as soon as there is a 
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recovery of cardiac and respiratory function or after applying the necessary 
treatment. 
1.10. Pharmacological targets for known ischemia-reperfusion injury 
mechanisms 
During last two decades, considerable basic research has been performed to target 
ischemia-reperfusion injury mechanisms. Main targets focused were cellular 
receptors including adenosine, opioids, adrenergic and muscarinic receptors studied 
by Lasley and Mentzer, 1998
119
; Vinten-Johansen et al., 1999
120
, effect of ion 
exchangers in ischemia reperfusion demonstrated  by Avkiran, 2001
121
 (e.g., Na+/H+, 
Na+/Ca2+),  nitric oxide pathways also reported by Ronson R et al.
122
 and intracellular 
signaling pathways activation e.g., PKC, tyrosine protein kinase, guanylate cyclase and 
MAP kinases have been investigated to understand cardioprotective mechanism of 
different drugs in ischemia-reperfusion injury
58
. Similarly, in this thesis, Sphingosine 
1-phosphate receptors were studied because of its well-established effect on 
inflammation, apoptosis and oxidative stress. 
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2. Introduction to Fingolimod (FTY720) 
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Sphingosine-1-phosphate 
 
Sphingosine-1-phosphate present in the plasma is mainly produced by endothelial 
cells, from erythrocytes, platelets and hepatocytes; is a bioactive lysophospholipid 
deriving from sphingomyelin, ubiquitous lipid cell membranes
123
. Sphingosine is 
formed by the enzyme sphingosine kinase. (Figure 2.1). 
 
Figure 2.1. The sphingolipid metabolism. The degradation of sphingosine-1-phosphate 
(S1P) by S1P-lyase is the only irreversible step in this pathway. Ceramide and S1P have 
antagonizing functions, which makes their balance essential for cell fate (adapted from 
Christina-Maria Reimann et al. 2015). 
 
The new therapeutic perspectives of Fingolimod result from increasing knowledge 
on sphingosine-1-phosphate (S1P) 
123
 including  cytoprotective, antioxidants, 
immunosuppressive 
124
, and its possible role in reducing ischemia-reperfusion 
injury
125
. The S1P mediate different physiological functions 
126
, including cell 
proliferation, differentiation and survival, as well as the reorganization of the 
cytoskeleton, the formation of cytoplasmic extensions, cell motility and chemotaxis, 
intercellular adhesion and formation of the junctions between cells. It is therefore 
involved in many physiological aspects of the body, such as immunity, maintaining 
the tone and pulmonary vascular smooth muscle, endothelial barrier integrity, 
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feature morphogenesis for the cardiovascular and the central nervous system. 
Although S1P is derived primarily from erythrocytes, other sources include the 
platelets, mast cells, endothelial cells, fibroblasts, and central nervous system
123, 127-
129
. Sphingosine-1-phosphate shall perform its functions through 5 subtypes 
including G-protein receptors S1P1, S1P2, S1P3, S1P4, S1P5 
130
. 
Recent studies have shown that sphingosine-1-phosphate reduces ischemia-
reperfusion injury in liver
131
, in the kidney
132
, and in the brain
133, 134
. Sphingosine 1-
phosphate as sphingosine are also able to increase the survival of cardiomyocytes 
during episodes of hypoxia; evidence emerged from in vitro studies 
135, 136
, it can 
also reduce the size of the infarcted area in productions of isolated hearts ex vivo 
137, 
138
. 
2.1. Fingolimod 
The drug Fingolimod (2-amino-2-[2-(4-Octyl-phenyl) ethyl]-1.3-propanediol 
hydrochloride), is a synthetic structural analogue of sphingosine that acts as a 
receptor agonist of sphingosine-1-phosphate, and represents a new frontier in the 
treatment of ischemia-reperfusion injury. 
The Fingolimod hydrochloride is a powder that is freely soluble in water, alcohol 
and propylene glycol. Currently, fingolimod represents as a unique sphingosine-1-
phosphate receptor agonist approved by U.S. Government agency "the Food and 
Drug Administration (FDA) for clinical use in human 
139
. 
 
Figure 2.2. Molecular structure of fingolimod 
2.1.1 History of Fingolimod 
The molecule of Fingolimod, also known as FTY720, was synthesized for the first 
time in 1995. Fingolimod is derived from chemical modification of a natural 
product, myriocin derived from Isaria sinclairii
140
 
141
. The active ingredient of 
natural origin for immunosuppressive agents found in 1992 by a group of Japanese 
researchers. On September 22, 2010, the Food and Drug Administration (FDA) had 
approved its use as first-line therapy for relapsing-remitting multiple sclerosis, and 
March 17, 2011, the European Commission has issued an authorization for placing 
commercially valid throughout the European Union. On November 22, 2011, 
fingolimod was approved commercially in Italy. 
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2.1.2 Use of Fingolimod in clinical setting 
Fingolimod was defined by the European Medicines Agency (EMA) for first-line 
therapy in patients with severe and rapidly progressing form MS, or as second-line 
therapy in case of failure with the use of Interferon-β (IFN-β).  In European Union, 
Fingolimod is approved for use as monotherapy, as Disease-Modifying Drug 
(DMD), in selected patients with a form highly active relapsing-remitting multiple 
sclerosis. The Efficacy of Fingolimod consists not only in reducing recurrence rates 
of MS, also improvement suggested by MRI monitoring for active disease, both 
compared with placebo than with INF-β and also in reducing the progression of 
disability compared to placebo 
142, 143
 
Fingolimod is different from existing therapies available for multiple sclerosis as 
primarily represents the first oral treatment in 0.5 mg capsules. For the treatment of 
MS, in the last two decades, first considerable progress regarding the effective 
control of the disease, especially for control of relapse
144
. Multiple sclerosis is a 
chronic inflammatory disease of the central nervous system, caused by an abnormal 
functioning of immune system.  Several disease-modifying drugs (disease-
modifying drugs, DMD) were approved but new molecules, such as Fingolimod, is 
the best treatment option for this condition. The DMD are molecules that Act on the 
causes of the disease, and currently, the most common DMDs are 
immunosuppressive agents, which work by reducing the action of the immune 
system and thus hindering the destruction of myelin, and immunomodulating agents 
that alter the delicate balance of the immune system, decrease its action, with the 
objective of limiting the attack on myelin
145
. 
Among the DMDs there is a mechanism of innovative action of fingolimod: its 
active metabolite "fingolimod-phosphate" resulting from the action of enzyme 
sphingosine kinases
139
, acts as a Sphingosine-1-phosphate receptor agonist receptor 
on S1PR1, S1PR3, S1PR4 and S1PR5
146
. Fingolimod-phosphate binding to its 
receptor agonist effect initially, but in the long term, it leads to internalization of 
receptors and consequent degradation to proteasome level, then in receptor 
inhibition
147, 148
. 
Fingolimod modulates receptor of sphingosine-1-phosphate and induces a 
lymphocyte surface down-regulation, making memory T lymphocytes, and T naive 
remain sequestered within lymph nodes, this mechanism has the potential to reduce 
the traffic of these cells "pathogenesis" in the central nervous system 
149, 150
. Since 
this is highly lipophilic, it can cross the blood-brain barrier and penetrate within the 
central nervous system 
151
 there is also increasing evidence; about a direct action on 
S1P receptors oligodendrocytes, astrocytes and neurons level 
152
. 
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2.1.3 Effects of Fingolimod 
Regarding the safety profile of the drug Fingolimod has generally proved safe and 
well tolerated, presenting medium grade adverse events including Sinus bradycardia, 
atrioventricular block, infections, increased liver enzymes, hypertension, and 
macular edema. The cardiovascular effects still constitute a major source of concern 
in the clinical setting, especially after the first dose of medication administered
144
. 
The cardiovascular effects of Fingolimod have been assessed through four clinical 
trials phase IV: TRANSFORMS, FREEDOMS, FREEDOMS II, and FIRST
142, 143, 153-
156
. In these studies is seen as reducing the heart rate is similar in patients with and 
without cardiovascular risk factors, a transient reduction and dose-dependence. 
Reducing the heart rate is observed only after the first dose, in long term therapy, it 
returns to baseline heart rate. Associated symptoms are rare, transient and usually 
without clinical consequences. A recent multicenter phase IV study called "The 
Evaluate Patient outcomes” (EPOC) Study confirmed these findings. These studies 
also suggested about the effect of Fingolimod by inducing a delay in atrioventricular 
conduction is uncommon and, when present, is transient, and usually recover 
without intervention. 
Additional features of this drug are that it does not change the duration of the QRS 
complex nor prolongs the QT interval 
157
 it also does not show significant effects on 
platelets function and counts.  About long term treatment, in 4 years, trial extended 
to FREEDOMS, the incidence of cardiovascular adverse events remained at the 
same level observed in the first two years of the study, indicating that long-term 
treatment has no impact on cardiovascular disease. This result was later confirmed in 
the trial, also extended to 4.5 years TRANSFORMS. And the effects on heart rate 
and atrioventricular conduction may recur when treatment is resumed after more 
than two weeks of suspension. 
2.2. The basic mechanisms of the cardiovascular effects of Fingolimod 
Cardiovascular effects encountered derive first by the presence of S1P receptors in 
the heart and blood vessels 
158, 159
 ; specifically, the receptor S1p1 predominates at 
the sinoatrial node, atrioventricular node, cardiomyocytes and endothelial cells, 
whereas the S1PR2 receptor is found primarily in arterial smooth muscle cells, cells 
which are at the same concentrations S1p1 and S1PR2 
160-163
. In the heart, S1P 
receptor activation causes the G protein receptor associated dissociation, followed 
by the activation of potassium channels called "inwardly-rectifying potassium G 
protein-coupled channels (GPCR) 
164
 potassium efflux; that follows goes to 
hyperpolarize the cell membrane, inhibiting depolarization and reducing the 
excitability and robotics 
165
. The result is, therefore, a reduction in heart rate. 
 51 
 
 
The S1P1 receptor internalisation is responsible for negative chronotropic effects of 
impermanence and dromotropic (respectively reducing the heart rate and speed of 
conduction of electrical impulses in the heart) induced by Fingolimod. Both 
atropine, a muscarinic receptor antagonist, isoprenaline, a beta-1 receptor agonist 
and beta-2 reverse the effects of fingolimod
166, 167
. In endothelial cells, S1P1 
receptor activation leads to phosphorylation of protein kinase B and the activation of 
endothelial Nitric Oxide Synthase (eNOS), events that increase the production of 
nitric oxide (NO)
168-170
.  
The S1P1 receptor in the smooth muscle cells of arteries lead to the release of 
calcium from intracellular reserves, increasing its concentration within the cells 
themselves and causing the contraction of smooth muscle cells and arterial 
vasoconstriction; Consequently the pressure does not change significantly in the 
acute phase following administration of Fingolimod for this balance between 
vasodilatation effect and vasoconstriction from it. 
Always smooth muscle level, as a result of the internalization of S1P1 (functional 
antagonism), S1PR2 and S1PR3 receptor binding is favored, which leads to the 
opening of calcium channels increasing intracellular concentration, causing smooth 
muscle cell contraction; these effects are responsible for the slight increase in blood 
pressure, about 1-2 mmHg, observed after two months of treatment with fingolimod 
0.5 mg/day reaching the peak pressure at six months and then remained stable 
142, 143
. 
The reorganization of the cytoskeleton and cell geometry and stabilization of 
intercellular junctions are further effects of activation of endothelial cell level S1P1 
171
; these effects strengthen the endothelial barrier and diminish the permeability. As 
in the arterial smooth muscle receptor agonism is transitory, even the endothelium 
due to internalization of receptors, followed by activation of S1PR2 and S1PR3, 
which leads to increased permeability of the endothelial barrier for breaking the 
intercellular junctions. 
2.3 Recommendations for safe use of Fingolimod 
For safe use of Fingolimod, with particular reference to cardiovascular adverse 
events, the European Medicines Agency (EMA) recommends an observation period 
of six hours after the first dose of the drug in all patients, to assess the signs and 
symptoms of bradycardia. Heart rate and blood pressure should be measured and 
recorded either before administration of the first dose every hour throughout the 
observation period; an electrocardiogram should be performed both before the first 
dose, then six hours later. During those six hours of continuous ECG monitoring is 
recommended viewing real time. The observation period should be extended for at 
least another two hours if the heart rate reached lower at after six hours; in the latter 
case, you should monitor until your heart rate does not increase. 
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The conditions that involve an extension of the period of observation until at least 
the next day, or until their resolution is: 
-          Heart rate less than 45 bpm upto first six hours 
-          QT interval ≥ 500 ms 
-          Second-degree atrioventricular block of new onset within six hours 
-          Third-degree atrioventricular block, regardless of the time of onset 
-       Need for drug therapy during the observation period. In this case, monitoring 
should be conducted for the night with medical assistance and should be repeated 
after the second dose of medication. 
2.4. Contraindication of fingolimod 
1. Patients predisposed to developing cardiac arrhythmia as those with heart block 
Mobitz II, third-degree heart block, sick sinus syndrome, or with a history of 
symptomatic bradycardia or recurrent syncope. 
2. patients such as those with little explanation tolerant ischemic heart disease, 
cerebrovascular disease, heart failure, patients with high blood pressure controlled, 
serious little sleep apnea just check, or a history of myocardial infarction or cardiac 
arrest . 
3. Patients being treated with class Ia antiarrhythmic drugs or class III. 
4. Patients taking heart rate lowering medications like beta-blockers and non-
dihydropyridine calcium channel blockers.  
Fingolimod is not absolutely contraindicated in such cases and may be administered 
when the benefits outweigh the risks. Monitoring should be extended to at least the 
first night in the first, second and fourth of the above patient's group of patients if 
they cannot suspend rate lowering drug therapy. 
Since the effects of Fingolimod on heart rate and atrioventricular conduction can 
occur at the time of resumption of the drug, also depending on the duration of the 
suspension, it is recommended to repeat monitoring after the first dose when therapy 
is interrupted for one or more days during the first two weeks of treatment, for more 
than seven days during the third and fourth week, or for two or more weeks if after a 
month or more of therapy. 
2.5. Mechanisms of Cardioprotection 
Sphingosine-1-phosphate on cardiomyocytes, binds to three G-protein coupled 
receptors: S1p1, S1PR2, and S1PR3, leading to activation of numerous signal 
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transduction pathways involved in cardioprotective action "intracellular" potentially,  
S1p1, in particular, is the main receptor of sphingosine-1-phosphate in 
cardiomyocytes, and typically activates downstream signal transduction pathways 
RISK and SAFE 
125, 172
.  Cardioprotective effects of Fingolimod are mediated by 
activation of RISK and SAFE, because both the antiapoptotic action, antioxidant 
action that is reducing the size of the MI, are reversed using concomitantly 
monoamine pathways RISK and SAFE. The main molecular Cascades can inhibit 
mitochondrial transition pore openings are the RISK, and SAFE pathways 
3, 173, 174
, 
and previous in vitro studies claim that S1P can activate these pathways 
138, 175, 176
. 
The downstream pathway S1P receptor-R is a potential therapeutic target peri-
infarct. Evidence arising from previous preclinical studies suggest that sphingosine-
1-phosphate represents a very promising pharmacological target for mitigating the 
damage from myocardial ischemia-reperfusion. In ventricular cardiomyocytes of 
rats, both adults and babies 
135, 136
sphingosine 1-phosphate, increased cardiomyocyte 
survival-during episodes of hypoxia. The S1P also induces resistance to ischemia-
reperfusion injury in rat hearts ex vivo studies of wild-type 
137
 and rat
138
. By these 
findings, the hearts of mice lacking the enzyme sphingosine kinase, an enzyme 
necessary for the synthesis of sphingosine-1-phosphate, develop upper ischemia-
reperfusion myocardial damage compared with controls 
177, 178
. Always confirming 
the role of S1P in size the myocardial damage, S1P receptor knockout mice-R show 
an area of larger infarct compared to controls 
179, 180
. 
The Metabolism of sphingosine also seems to be a key mediator in Preconditioning 
and Post conditioning, recognized strategies Cardioprotection 
2
. In fact, both the pre 
and postconditioning can reduce the size of the MI, which does not take place in the 
hearts of sphingosine kinase or missing S1P receptor(Fig. 2.3) 
138, 177, 178, 180
. The 
mitochondrial transition pore opening represents the final step that leads to apoptosis 
of cardiomyocytes in ischemia-reperfusion injury and is able to trigger oxidative 
stress that characterizes it; therefore, preventing the mitochondrial transition pore 
opening you can reduce infarct size 
181, 182
. 
Previous studies have shown great benefits in immunosuppression of the prevention 
of ischemia-reperfusion injury
183
. Fingolimod is a drug which, among other effects, 
as already discussed about its use in MS, also exerts an immunomodulatory action 
able to regulate the traffic of lymphocytes from peripheral blood and tissues to 
lymph nodes and reduces the output of lymphocytes from lymph nodes themselves 
123, 139
. 
In a recent study of 2014 conducted by Wang G et al. 
155
 using a mouse model of 
spontaneous coronary atherosclerotic occlusion based, saw itself as in mice treated 
with Fingolimod you got a reduction in the size of the infarcted area (ex vivo) as 
well as lower mortality. In these same mice is there has been a reduced count of 
CD4 and CD8 T cells and an increased number of T regulatory cells, suggesting how 
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the immunosuppressive effects of Fingolimod contribute to its cardioprotective 
properties.   
Together these findings emphasize as sphingosine-1-phosphate and synthetic 
analogue Fingolimod promising may have a role in the prevention of ischemia-
reperfusion. Several evidence claims that average Fingolimod cardioprotective 
effects: preliminary in vitro studies have shown that S1P receptor activation 
mediated by this drug armies antiapoptotic effects, reducing the loss of 
cardiomyocytes in hypoxic conditions
125, 175, 184
. Studies on preparations of mouse 
and rat isolated hearts have shown that Fingolimod is also able to reduce ischemia-
reperfusion injury and to improve myocardial function
184
. Despite these different 
confirmations about various cardioprotective effects, they have not yet been studied 
in large animals models. 
As reported in the study by Santos-Gallego et al in a model of myocardial ischemia-
reperfusion conducted on pigs, according to a short Protocol term (Administration of 
Fingolimod 15 minutes before reperfusion or saline in controls) and a long-term 
Protocol (Administration of Fingolimod 15 minutes before reperfusion or saline in 
controls; the same treatment then once a day for three days) 
185
 S1P receptor 
activation , mediated by Fingolimod, given before the myocardial reperfusion injury, 
resulting in a significant reduction of cardiomyocyte apoptosis in the outskirts of 
ischemic myocardium, quantifiable by Terminal deoxynucleotidyl transferase dUTP 
Nick End Labeling (TUNEL); this technique allows to detect fragmented DNA 
through the labeling of nucleic acid Terminal residue. It is commonly used to detect 
fragmented DNA resulting from the cascade of activation of apoptosis and relies on 
the presence of breaks in the DNA sequence that can be made evident through the 
use of terminal deoxynucleotidyl transferase (TdT), an enzyme that catalyses the 
addition of dUTP, subsequently detected by a marker.  
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Figure 2.3. Regulation and function of S1P (A) The diagram depicts some of the negative 
and positive regulators of SK1 activity and the synthesis and location of the SK1/S1P 
pathway either present in the heart or derived experimentally. (B) A second isoform of SK 
(SK2) is also responsible for the S1P generation. The location of S1P generation within the 
cell may determine its effect, but the outcomes of such location-based effects have not been 
determined(Adapted from Karliner J et al. 2008)
186
. 
2.5.1. Anti-apoptotic action 
To reduce cardiomyocyte apoptosis, Fingolimod mediated through the activation of 
signal transduction pathways "Reperfusion Injury Salvage Kinase (RISK) and 
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Surviving Activating Factor Enhancement (SAFE); to confirm this, the simultaneous 
administration of Wortmannin, an inhibitor of pathway RISK (including 
Akt/ERK/GSK-3 β), or AG490, SAFE pathway inhibitor (Janus kinase/STAT3), 
delete the antiapoptotic effect towards the cardiomyocytes. As further data in favour 
of activation by Fingolimod, pathways that regulate the protection of 
cardiomyocytes ischemia-reperfusion damage, RISK and SAFE 
3, 174
, it has been 
shown that Akt, GSK-3β, ERK1 1/β and phosphorylated STAT3 are markedly on 
the edge of the ischemic myocardium in pigs treated with Fingolimod after 1 day 
after myocardial infarction, reflecting the cardioprotective effect. In contrast, Akt 
and ERK1/2 signalling pathways are less remote myocardial infarcted 
phosphorylated after one month after myocardial infarction, to witness a minor 
remodelling. So the downstream signalling cascades of S1P-R mediate the activation 
of anti-apoptotic pathways, in the acute phase, and in the later stages reduce 
remodelling. Santos-Gallego et al. 
185
 demonstrated how Fingolimod induces 
significant Akt phosphorylation, ERK1/2, STAT3-β, and 24-hour GSK3 after a 
myocardial infarction, increased compared with controls. Therefore, in a porcine 
model of ischemia-reperfusion, Fingolimod has proved able to activate both RISK 
and SAFE in the acute phase of myocardial infarction. 
The signal transduction pathways, including Akt and ERK1/2, are important stimuli 
for growth and survival of cardiomyocytes; although their short-term activation 
results in decreased apoptosis, in the long run, leads to cardiomyocyte hypertrophy. 
Long-term activation is one of the key molecular features of left ventricular 
remodelling, negative, in the post- infarction
187, 188
. The evidence of the 
antiapoptotic action of Fingolimod is further supported by detection from one side of 
a reduced activation of proapoptotic proteins Bax and Caspase-3, the other to an 
anti-apoptotic protein such as Bcl-2 expression increased and the kinase C-ε in pigs 
treated with FTY720. As a result of anti-apoptotic effects of Fingolimod, this 
medication can significantly reduce the size of the infarcted area. 
2.5.2. Antioxidant action 
Cardioprotective effects attributable to Fingolimod, the antioxidant is demonstrated 
by reduced myocardial ischemic area exists at the edge of oxidative stress in pigs 
treated with this medication, associated with a concentration of 8-
hydroxydeoxyguanosine, markers of oxidative stress; always in support of this 
aspect of Fingolimod, antioxidant superoxide dismutase enzyme activity is increased 
in animals treated with FTY720. 
2.5.3. Attenuation of ischemic cardiomyopathy 
Fingolimod actions to attenuate myocardial damage includes,  reducing the extent of 
myocardial infarcted mass acting on both the absolute and the percentage of the 
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infarcted left ventricular myocardium. As evidenced by the Santos-Gallego et al, 
Fingolimod can increase the protection for infarction of approximately five times 
compared to controls that have not been given the drug
185
. 
Besides the reduction of the infarcted area, Fingolimod has proved capable of 
improving left ventricular systolic function, as evidenced by increased Left 
Ventricular Ejection Fraction (LVEF), assessed by cardiac magnetic resonance, 
performed for a week to a month after myocardial infarction; also cases treated with 
Fingolimod have a greater contractile reserve compared with controls. These 
findings are important because of both improved LVEF that the presence of proper 
contractile reserve, are associated with more favourable outcomes 
189, 190
. 
One of the worse complication of myocardial infarction is definitely the structural 
remodeling that characterized by, dilation, compensatory hypertrophy and changes 
in left ventricular sphericity. Fingolimod reduces the extent of left ventricular 
remodeling, visible as reduced left ventricular mass or to one week to one month 
after myocardial infarction; In addition, compensatory hypertrophy of the wall, the 
wall thickness index calculated by echocardiography, is lower than in the Group of 
pigs treated with Fingolimod. Santos-Gallego et al. was the first to report that 
Fingolimod not only reduces ischemia-reperfusion injury and the size of the 
infarcted area but also resizes the development of ischemic cardiomyopathy. 
The effects on remodelling operated by minor evidence of fingolimod are therefore 
caused by structural changes in the left ventricular load, including a reduced dilation 
of the heart confirmed by echocardiography and the MRI both. The anti-remodeling 
is also visible at histological level, as demonstrated by the reduced deposition of 
collagen in the myocardial interstitium.  Fingolimod treated group; also have small 
cardiomyocytes, confirming as Fingolimod go to alleviate post-infarct remodeling 
by microscope. The attenuation of the anatomical remodelling is supported by lower 
neurohormonal activation, supported by reduced levels of Aldosterone and blood 
Metanephrines; These findings emphasise as Fingolimod group in harmony with the 
best anatomical left ventricle-level outcomes in cases treated with this drug. 
2.5.4. Role of sphingosine-1-phosphate and HDL in Cardioprotection 
About 60% of the plasma is carried by HDL S1P 
65
. More than 30 years ago it was 
shown that cholesterol carried by High-Density Lipoproteins (HDL) is strongly and 
in inverse proportion linked to coronary artery disease. Recent studies assigning 
HDL properties that go far beyond the capacity to promote cholesterol efflux: these 
represent the largest lipoproteins transport mediated by binding to S1P, transporter 
apoprotein M associated with HDL (apoM), and S1P is active in various HDL-
associated signal transduction cascades through activation of its receptors on various 
cell types 
172, 191
.  
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HDL protect against CAD properties have been attributed to the ability of S1P to 
preserve endothelial function and inhibit proinflammatory leukocyte level signalling 
192
. This aspect is important because, in the evolution of myocardial infarction, 
accumulation of inflammatory cells in the infarcted area occurs rapidly after 
initiation of the procedure of reperfusion and reach at peak level of  neutrophils 
infiltration usually after  24 hours 
193
.  
 
AIMS OF THE STUDY 
 
 
      
HYPOTHESIS 
 
We hypothesized that the injury induced by myocardial ischemia reperfusion can 
be attenuated by sphingosine 1-phosphate activation via the activation of 
Akt/Erk1/2 pathways, inhibition of apoptosis and inflammation, reduction of 
oxidative and nitrative stress. 
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SECTION II 
 
3. Materials and Method 
 
3.  Introduction 
This thesis consists of experimental studies; all were in vivo rat model of global 
myocardial ischemia-reperfusion injury. The surgical preparation and techniques for 
particular experimental models have been mentioned in the following section. For 
all experimental studies, tissue and blood were collected to analyze for further 
analysis to understand the mechanism of cardioprotection in our experimental 
models with fingolimod.  
3.1. Animals 
The experimental study was held at C.I.R.S.A.L. (Interdepartmental Research Centre for 
Laboratory Animals) of the Biological Institutes, University of Verona, Verona, Italy. The 
housing, handling and sacrifice of animals were carried out according to the regulations 
(Declaration of Helsinki and "Guide for the Care and Use of Laboratory Animals” - Institute 
of Laboratory Animal Resources - National Institutes of Health) after approval of the Ethics 
Committee and the Ministry of Health. We used healthy Sprague-Dawley (SD) male rats 
weighing 300-350 grams kept in rooms with controlled temperature and humidity with 
typical light-dark cycle fed with standard feed and water.  
3.2. Cardiac arrest by inducing VF 
Cardiac arrest is one of the leading causes of morbidity and mortality in Western 
countries. Despite initiatives for emergency medical services, and better techniques 
of defibrillation, the rate of survival following cardiac arrest (CA) is still very low. 
In fact, of the 0.7 million patients per year  undergo resuscitation after CA, out of 
them survival rate is 3-10%
194
. Ventricular fibrillation (VF) is the most common 
cause of sudden cardiac death
195
. The incidence of VF-induced sudden CA is over 
10 per 100,000
196
. In this field of cardiovascular science, on developing CA models 
that encompass most cardiovascular variables observed in routine human cases and 
that may play additional important role to study different effect of CA in heart and 
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brain. Presently, many models are available to induce CA in rats, including CA 
induction by a rapid intra-atrial injection of potassium chloride, delivering current to 
the right ventricular endocardium, trans-oesophageal cardiac pacing, transthoracal 
electrical fibrillation, , chest compression, compression of the heart vessels against 
the chest wall by use of a microsurgical instruments, asphyxia and simultaneous 
aortic occlusion and right atrial occlusion created by an arterial and venous balloon 
catheter respectively. All of these models have a few advantages and disadvantages. 
Although the VF induced model mimics the “square wave” type of myocardial insult 
(rapid loss of pulse and pressure) commonly seen in adult humans at the onset of 
CA. Here we will use a modified, simple, and reliable VF technique induced in rats 
as a model of CA that could be useful in studying the mechanisms of myocardial 
ischemia-induced injury and effect of fingolimod on it. 
3.2.1. Anesthesia Induction 
Rats were anesthetized using 5% isoflurane in 50% O2 in a 5 liter plastic induction 
box. After induction, oro-tracheal intubation was done with a 14G cannula, and the 
rats were ventilated by a mechanical device for small animals (Harvard Model 687, 
Harvard Apparatus, Holliston, MA). The tidal volume was 6 ml/kg, and the 
breathing rate was 50–60 breaths/min with an air and oxygen mixture/FiO2 = 0.5). 
Arterial blood gases were assessed to adjust ventilation to maintain arterial CO2 
tension (PaCO2) of 35-45 mmHg. Anesthesia was maintained with 2.5% isoflurane, 
and intraperitoneally pancuronium-bromide (2 mg/kg) was used to maintain muscle 
relaxation. Rats were secured in supine position on a heating board. Throughout the 
experiment, ECG was monitored by using limb leads. The right femoral artery was 
isolated and inserted a miniaturized catheter of 2-Fr diameter (model SPR 838, 
Millar Instruments, Houston, TX) for the monitoring of systemic blood pressure. To 
administered treatment, femoral vein cannulation was done with 24G cannula. 
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3.2.2. Experimental model for Cardiac arrest and Extra Corporeal Resuscitation 
in rat 
Access to the heart was achieved through a median sternotomy followed by the 
opening of the chest with a retractor. In order to speed up and simplify the 
procedures after the cardiac arrest has arranged for the preparation of animals for 
assistance with extracorporeal device cannulation. After recording, the skin and the 
subcutaneous planes in the midline of the neck have been identified as the trachea 
and immediately to the right of neurovascular bundle. A venous cannula (a modified 
version with 4 holes of a caliber of 5 French catheter) was advanced through the 
right external jugular vein to the right atrium allowing an excellent Venous drainage. 
The left common carotid artery was cannulated with a 24 G  
 
 
Figure 3.1. Schematic diagram of procedural steps for induction of ventricular fibrillation-
induced cardiac arrest(adapted from Kunjan R et al. 2013)
197
. 
catheter, advanced to the aortic arch and connected to the arterial perfusion of the 
circuit as explained in flowchart (Fig. 3.2) Full heparinization (heparin 500 IU /kg) 
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was performed immediately before the start of extracorporeal circulation. After 
opening the pericardium it proceeded induction cardiac arrest which was obtained by 
ventricular fibrillation using a defibrillator disbursing a 3.5 mA current at 60 Hz 
released at the level of left ventricular epicardial region (Fig. 3.2). The current flow 
was maintained for 3 minutes in order to prevent a spontaneous depolarization and 
cardiac arrest was maintained for10 minutes, after which reperfusion occurred 
through extracorporeal circulation. Mechanical ventilation was stopped during 
induction of VF.  
 
 
Figure 3.2. Electrical induction of VF induced CA model, Yellow arrow indicating source 
for electrically induced VF, White arrow indicating left ventricle. 
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3.3. In Vivo experimental rat model of Cardioplegic arrest 
3.3.1. Animal preparation 
After a pre-anaesthesia with vapours of diethyl ether, rats were orotracheal intubated 
with an atraumatic tube constituted by a venous cannula of 14 G. The rats were then 
ventilated with a mechanical respirator for rodents (Inhale, Harvard Apparatus, 
Holliston MA) with a mixture of oxygen and anaesthetic Sevorane 2% (Abbot 
Laboratories, Queenborough, UK) that guaranteed anaesthesia for the duration of the 
procedure, with a fraction of inspired oxygen (FiO2) of 90%, a tidal volume of 10 
ml/kg and a frequency of 70 breaths per minute, 0.1 mg/kg of vecuronium bromide 
were administered to obtain complete muscular relaxation and repeated if needed. 
During the surgical procedure, room temperature was maintained between 23° and 
25° C and a layer of isolating material (cork) was placed between the animal and the 
operating table. 
Rats were placed in supine position, thoracic area, ventral surface of the neck and 
hind legs were shaved, and skin was disinfected with chlorhexidine. A thermocouple 
microprobe was inserted into the rectum to monitor animal temperature during the 
experiment. Electrocardiogram (ECG) electrodes were attached on both front limbs 
and left hind limb. The right femoral artery was isolated, and a miniaturised catheter 
with a diameter of 2-Fr (model SPR 838, Millar Instruments, Houston, TX) for 
continuous monitoring of systemic blood pressure was inserted. Subsequently, it was 
also cannulated the femoral vein with a 24-G canula (Delta Med S.p.A. Viadana 
(MN) Italy), followed by administration of 500UI / kg heparin to ensure patency and 
to be ready for CPB. 
3.3.2. Surgical procedure 
Access to the heart was achieved through a median sternotomy; chest was kept open 
with a retractor. After incision of skin and subcutaneous planes in the midline of the 
neck, trachea was identified. A venous cannula (a modified 4-hole catheter calibre of 
5 French) was advanced through the external jugular vein to right atrium allowing an 
excellent venous drainage. The left common carotid artery was cannulated with a 24 
G (Delta Med S.p.A. Viadana (MN) Italy) catheter that was advanced to the aortic 
arch and connected to the line of arterial perfusion circuit. Also, 0.2 mg 
pancuronium was administered before CPB. Muscle relaxation was used to prevent 
spontaneous ventilation that often interferes with the venous return due to movement 
of the mediastinal structures about the venous outflow cannula. 
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Figure 3.3. Schematic view of extracorporeal life support 
3.3.2. Perfusion circuit 
The extracorporeal circulation circuit was constituted by a roller pump (Stockert 
SIII, Sorin, Germany), an hollow fiber oxygenator (Sorin, Mirandola, MO, Italy), a 
venous reservoir connected to a vacuum with a pressure regulator -30 mmH2O to 
facilitate venous drainage, all connected by plastic tubing with 1.6 mm inside 
diameter. The total volume of filling of the extracorporeal circuit including the 
oxygenator was 6 ml and constituted by colloid solution and Ringer's lactate 
solution. The exchange surface of the gas was 450 cm2 and the heat exchange 
surface area of 15.8 cm2. Once prepared venous and arterial accesses rat was 
connected to the circuit of CPB and maintained with a flow rate of 80-100ml / 
kg/min and a range of mean arterial pressure of 70-90 mmHg. After ensuring the 
adequate venous drainage and appropriate hemodynamic stability mechanical 
ventilation was suspended.  
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3.3.3. Cardioplegic Arrest 
After 10 minutes of CPB ascending aorta was clamped with a vascular clamp and 
cardiac arrest was induced by administration of 2 ml cardioplegia (St Thomas 
solution) in ascending aorta. The CPB flow rate was adjusted as needed to maintain 
a constant venous reservoir blood level. After 10 min of cardiac cardioplegic arrest 
aortic clamp was removed, after few minutes heart usually started beating 
spontaneously, CPB was maintained for another 60 min. During the entire 
procedure, mean arterial pressure remained higher than 45 mmHg. Subsequently, 
this was suspended, and weaning from CPB was completed with reinfusion of the 
blood in the circuit before rat sacrifice and removal of brain and heart. 
 
 
Figure 3.4. Roller pump and Oxygenator during extracorporeal circulation 
Vacuum 
Vacuum 
Venous Source 
Pump 
Oxygenator 
Arterial source 
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Figure 3.5. Veno-Arterial Cannulation during Extra Corporeal Circulation 
3.4. Heterotopic Cardiac Transplantation Model of Rats 
A technique for a heart transplant in small animals was first described by Abbot et 
al
198, 199
. And then by Ono and Lindsey who made some changes
200, 201
. Apart from 
these few have described the surgical techniques and anaesthetic management of 
heterotopic cardiac transplantation in rodents
202
.  
3.4.1. Description of model 
For each experiment planned using 2 male rats weighing about 350-400 g. One rat 
was used as a receiver and the other as a donor.  
3.4.2. Animal Preparation  
The donor's rat chest was opened through an incision with Mayo curved scissors, to 
prevent injury to the major blood vessels and lungs. The cardiac exposure was done 
by removal of the pericardial sac. The heart was perfused with St-Thomas at 4 °C 
temperature, with the composition of St-Thomas nine mL and of 1 mL heparin 
sodium, 1000 U / mL. A 6-0 proline tie was used around the superior vena cava 
(SVC) and inferior vena cava (IVC). Heart perfusion was obtained by inserting a 24-
Arterial Cannula 
Lt. Carotid Artery 
Venous cannula 
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G needle into IVC. Five serial injections of 2 mL volume were delivered within 4 to 
5 minutes, to achieve an equal volume of blood drainage after each 2mL infusion. 
After infusing first 2-mL injection, the SVC was tied with 6-0 proline. Later, after 
infusion of the remaining solution, IVC was also tied. Perfusion is recommended at 
the rate of slow speed to prevent coronary vascular damage. The transverse sinus 
was found under the pulmonary artery and ascending aorta with 45-degrees curved 
forceps, carefully to avoid injury to the left atrium with the tip of forceps. The 
pulmonary artery and ascending aorta were cut together by using a 60-degree sharp 
angled scissors least 4 to 5 mm above the origin (Fig 1A). The SVC was dissected 
over the knot, and the IVC was dissected below the knot. The heart was lifted with a 
4-0 proline suture placed under it, then moved downward, and also the suture was 
tied around the pulmonary veins. The donor's heart was preserved in St-Thomas 
solution at 4 ° C on the ice while preparation of the recipient rat.   
3.4.4. Graft Implantation 
The animal was positioned with head toward the left side of the surgeon. The 
recipient rat abdomen was opened through a midline incision with Mayo curve 
scissors. The intestines have been moved to the left side and covered with moistened 
gauze with normal saline. The major vessels (IVC to the right of midline and 
abdominal aorta left side of the midline) were dissected and separated from the 
surrounding tissue gently with a cotton tip, using mini forceps only when necessary. 
The small iliolumbar veins were exposed and tied with 6-0 silk sutures or cauterised. 
Vascular mini-clamps with delicate teeth distally entered first, then proximally, 
abdominal aorta and IVC, isolation a 1.2-cm segment of the vessels between the 
jaws. The aorta was incised near the distal terminals using a 24-G needle to drain the 
blood.  Extra-fine scissors were used to perform an arteriotomy of about 4 mm, with 
special care not to damage the posterior wall. The lumen was gently washed with a 
heparinized St-Thomas solution. The donor's heart was placed in the field in 
preparation for end-to-side anastomosis. The organ was positioned with the apex 
towards the tail and the aorta above the pulmonary artery. The aortic anastomosis 
was performed by inserting a point of anchoring the proximal end of the arteriotomy 
(out-in) the abdominal aorta, and then a point on the aorta graft-out, and was set with 
a triple knot .  A second (out-in) of the suture anchor has been placed on the 
opposite side of the first point-out the distal end of the arteriotomy. After positioning 
the second suture anchor, a continuous suture (5- 6 points) was performed on the 
front wall from the proximal end towards the distal end of the arteriotomy. The heart 
graft has been repositioned by turning it over to expose the back wall. The 
anastomosis was completed with a continuous 
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Figure 3.6. Image showing recipient and transplanted heart 
running suture. The graft has been turned back to expose the anterior wall of the 
graft where the pulmonary artery had collapsed over the aorta. An opening 5 to 7 
mm in length was made in the receiving IVC with scissors, and the lumen was 
flushed with the heparinized St-Thomas solution to remove any thrombus. The IVC 
opening should be more (5 to 6 mm in length) than the aortic opening to anastomose 
the pulmonary artery appropriately. An out-in stitch was kept on the distal part of the 
pulmonary artery and in-out at the distal part of the IVC opening. A continuous 
suturing was performed first a longer posterior wall and then at the anterior part of 
pulmonary artery-IVC . Before releasing micro vessel clamps, the suture line has 
been thoroughly checked for any expected leakage point. First, the distal clamp was 
released, and then after 30 seconds the proximal clamp. Anastomosis was checked 
Transplanted heart 
Recipient Heart 
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throughout suture point, and if there was some bleeding point, that could be 
controlled using cotton tips and oxidised cellulose (Tabotamp, Ethicon, and 
Neuchatel, Switzerland). Within few seconds after reperfusion, spontaneous heart 
contractions were observed in grafted heart. The total ischemia time in a successful 
operation ranged from 40 to 60 minutes. The abdominal structures were replaced 
with care to avoid torsion of intestines. The incision was closed with a non-
absorbable continuous suture (4-0 proline) that included the fascia, muscles and 
separate suturing was done for skin. The rat was kept under the heat lamp for 15 
mins to achieve normothermia. And rats were kept in a warm and oxygen rich room 
until sacrifice or other measurements. 
Removing the weight, a constant ligation pressure could be applied and easily 
released.  Leads were implanted subcutaneously in a lead II electrocardiogram 
(ECG) configuration. Animals were then positioned in a specially designed Plexiglas 
cradle fitted to the occlusion device. Rats stabilized for 15-20 minutes before arrest. 
Ischemia was visually confirmed by regional cyanosis downstream of the occlusion 
or changes in the ECG. The heterotopic transplanted heart in vivo rat model shown 
in (Fig. 3.6). 
3.5. Hemodynamic monitoring and measurements 
After recording, the skin and the subcutaneous planes in the midline of the neck 
were identified as the trachea immediately to the right of neurovascular bundle. The 
right carotid artery was isolated, linked cranial and caudal clamped. After making a 
small cut with microsurgical scissors and inserted miniaturized catheter of 2-Fr 
diameter (model SPR 838, Millar Instruments, Houston, TX) into the carotid artery 
(Figure 3.7). 
 
Figure 3.7. Conductance catheter for monitoring of pressures and volumes in the left 
ventricle (Millar Instruments, Texas, USA). 
This catheter was then connected to the relevant transducer and then to the unit 
Power-Lab (AD Instruments, Colorado Springs, CO). The latter, through the USB 
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port, has been connected to a computer for real-time display of pressure-volume 
curves and data logging using the Chart software (AD Instruments). With this set-up 
the catheter to conductance was introduced into the carotid artery and advanced to 
the left ventricle, the correct position is reached by following the trend of the 
pressure curve.  
 
Figure 3.8. Carotid Catheterization(a) and registration through theChart software that 
shows the transition from the aorta to the left ventricle (b). 
 
The signal is recorded continuously with a sampling rate of 1,000 / s thus being able 
to monitor the hemodynamic changes during the whole duration of the intervention. 
The parameters considered were Left Ventricular End-Systolic Pressure (LVESP),  
Left Ventricular End-Diastolic Pressure (LVEDP), Ejection Fraction (EF), Stroke 
Volume (SV), maximum increase in systolic blood pressure (+ dP / dt) and 
maximum decrease in diastolic blood pressure (- dP / dt) , Maximal Power (max 
PWR), Adjusted Preload Maximal Power (PAMP) and tau-Weiss constant time. The 
calibration of the conductance system was obtained as previously described by 
Pacher and colleagues. Briefly, nine cylindrical holes of known diameter variable 
between 2 and 11 mm inserted into a 1 cm high block were filled with the 
heparinized whole blood of rats. In this calibration, the volume conductance-linear 
regression of the absolute volume contained in each cylinder compared with the raw 
signal obtained through the catheter in conductance was used for the volume 
calibration formula. 
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3.6. Tissue Analysis 
3.6.1. Paraffin processing and embedding 
Following fixation myocardial tissue was done in formalin. Myocardial tissue was 
placed into labelled plastic embedding cassettes and washed in running water for 30 
minutes before being dehydrated through a series of alcohols and liquid paraffin 
(Table 3.1). Following processing, each 3mm slice was embedded in fresh paraffin 
and left to set before cutting. 
3.6.2. Cutting 
Sections (3m) were cut using microtome from paraffin blocks. Sections were 
floated in the water bath with maintained temperature of 40 °C to avoid any crease, 
and then sections were placed on a polarised microscopic slide for immune staining 
and green for histology. Sections were exposed for 1 hour at 60°C to let them fix on 
the slide and stored until required. 
3.6.3.Histopathology 
Hematoxylin and eosin (H&E) staining was used, to assess the quality of sections, 
proper tissue fixation, and processing. H/E was also used to see morphological 
changes in the myocardial cell in different experimental groups.  
3.6.3.1. Hematoxylin and Eosin staining 
Fresh sections mounted on slides were kept in an oven at 60°C for 60 mins then de-
deparaffinized in xylene for 20 mins following serial rehydration through a 100% (1 
x 5 mins), 90% (5 mins) > 75% (5 mins), and rinsing with tap water (3 mins). All 
sections on each slide were immersed in a hematoxylin solution (Thermo-Scientific, 
Loughborough, U.K.) for 30 seconds and then washed in flowing tap water. For 
differentiation, acid alcohol solution (1%HCl in 75% ethanol) was used to immerse 
for 10 seconds. Sections were rinsed in tap water for 2-3 minutes before „bluing' in 
tap water solution Scott's using (2% MgSO
4
).
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Table 3-1 The sequence of solutions heart tissue was processed through before 
paraffin embeddin. 
Stage Solution Temperature Time in Solution 
1 Running water ~ 15-20°C 30 mins 
2 70% Ethanol Room Temp. 30 mins. 
3 70% Ethanol Room Temp. 30 mins. 
4 90% Ethanol Room Temp. 30 mins. 
5 90% Ethanol Room Temp. 30 mins. 
6 100% Ethanol Room Temp. 30 mins. 
7 100% Ethanol Room Temp. 30 mins. 
8 Xylene Room Temp. 30 mins. 
9 Xylene Room Temp. 30 mins. 
10 Liquid paraffin 65°C 30 mins. 
11 Liquid paraffin 65°C 30 mins. 
12 Liquid paraffin 65°C 30 mins. 
13 Liquid paraffin 65°C Overnight 
 
and 0.35% NaHCO
3
) for next 2 minutes and then another 2 minutes washed in tap 
water. Slides were checked under the light microscope to assess the quality of 
nuclear hematoxylin staining.  If nuclear staining was too dark, acidic alcohol 
solution was used to light hematoxylin and then sections were immersed in alcoholic 
eosin Y solution (Surgipath., Cambridge, UK) for 3 mins following serial use of 
ethanol 75% (5 mins) > 85% (5 mins) > 100% (5 mins (2times)) and xylene (20 
mins) for dehydration, prior to Mount cover slips using polyvinyl.  
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3.6.3.2. Counterstaining with hematoxylin 
The immunostained sections were counterstained with hematoxylin to aid 
delineation of anatomical features following DAB visualisation; sections were 
rinsed for ten mins and then immersed in hematoxylin, differentiated and „blued,' 
then dehydrated through alcohols and xylene and mounted with cover slips using 
DPX as above. 
3.7. Immunohistochemistry 
All sections used for immunostaining were adjacent to those who had undergone 
histological analysis. All immunostaining was conducted by the author unless 
otherwise stated. 
3.7. Masson Trichrome Staining 
As the name implies, three dyes are employed selectively staining muscle, collagen 
fibres, fibrin, and erythrocytes. The general rule in trichrome staining is that the less 
porous tissues are colored by the smallest dye molecule; whenever a dye of large 
molecular size can penetrate, it will always do so at the expense of the smaller 
molecule. Others suggest that the tissue is stained first with the acid dye, Biebrich 
Scarlet, which binds with the acidophilic tissue components. Then when treated with 
the phosphor-acids, the less permeable components retain the red, while the red is 
pulled out of the collagen.  
3.7.1. Interstitial fibrosis determination 
A myocardial tissue from the left ventricle was fixed in phosphate-buffered 10% 
(vol/vol) formaldehyde (pH 7.2) and embedded in paraffin. Three-micron sections 
were stained with Masson's trichrome to evaluate fibrosis as mentioned in the 
previous study 
203
. Measurements (×20 magnification) were analyzed multiple 
microscopic fields per section and expressed as a collagen volume fraction. 
Randomly left ventricle sections were stained from each experimental. 
3.8. TUNEL assay 
(Terminal deoxynucleotidyl transferase mediated X-dUTP nick end labeling). 
TUNEL assay has been done on paraffin fixed tissue using the protocol given by kit 
manufacturers(Sigma Aldrich). 
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3.9.1. Rehydration  
Rehydration was done using xylene for 20 mins, following series of ethanol 100%, 
100%, 90%, 80% and 70% 5 mins each. Excess water was removed using Kim-
wipe, circles made around sections using PAP pen.  
3.9.2. Proteinase digestion 
Permeabilization of the tissue section with 15 µg/ml Proteinase K (Gibco BRL) in 5 
mM EDTA and 5 mM Tris 7.5. Incubation was done for 20 minutes at room 
temperature. Proteinase K incubation time was adjusted for 15 minutes.  
3.9.3. TUNEL labeling 
 TUNEL cocktail 
The cocktail was prepared each time for new experiment and for control slides only 
PBS was used. New Eppendorf tubes were used each time for each experiment. 50ul 
TUNEL solution was used for each section to cover adequately. 
Positive control – DNAse1 treatment  
Incubation of positive control sections done for 10 min. at room temperature in 1500 
U/ml DNAse1 in 20 mMTris pH 7.5, 10 mM MgCl2, 1 mg/ml BSA.  
3.9.4. Counterstaining 
Counter staining was done with Gel Mount-DAPI (Sigma-Aldrich) as a final step. 
TUNEL signal observed with blue light excitation (450 – 500 nm), fluorescein 
emission was green.  
3.9.5. Image acquisition 
Using the digital camera, because of significantly shorter exposure times as FITC 
fluorescence is quickly bleached by light. Focus area of interest using UV 
illumination, acquired DAPI image, then switched to blue illumination without 
moving the specimen position, captured the TUNEL image. 
3.10. Blood samples analysis 
At the end of experiments, according to study design blood samples were collected 
from the abdominal aorta and sent to Hematological and Biochemical Laboratory, 
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Azienda Ospedaliera Universita di Verona for blood counts, cardiac biomarkers and 
inflammatory mediator‟s measurement. 
3.11. High-Energy Phosphates  
The high-energy phosphates Adenosine MonoPhosphate (AMP), Adenosine Di-
Phosphate (ADP), Adenosine Tri-Phosphate (ATP), and phosphocreatine (PCr) were 
analyzed by high-performance liquid chromatography as described 
previously
204
.
16
 Energy charge (EC) was calculated according to the following 
formula: EC = (ATP + ½ ADP)/(ATP + ADP + AMP). 
3.12. Oxidative Stress Measurement  
To investigate, Malondialdehyde (MDA) and Reactive Oxygen Species (ROS) after 
24 hours, myocardial tissue were processed at 37 °C, 5% CO2 95% air atmosphere 
for 60 min according to the manufacturer's protocol. The myocardial tissue were 
incubated at 37 °C for 30 min in PBS (in mM: 137 NaCl, 2.7 KCl, 9.8 Na2HPO4, 
1.5 KH2PO4, pH 7.3) containing 10 μM.  Absorbance at 490 nm was measured with 
a microplate reader (ELx800; Bio-Tek, Winooski, VT, USA). 
3.13. Western Blotting 
3.13.1. Antibodies  
Western blot was used to investigate the levels of proteins in heart tissue 
homogenate. Details of primary and secondary antibodies and their concentration 
used can be seen in Table 3.3. Negative control was also used, where membrane was 
exposed and processed in all aspects except an addition of primary antibodies.  
Although, the Western blot can be considered reliable, relatively low in cost, time-
saving method for quantification of protein. There must be some potential deficits 
considered while using it including nonspecific binding of antibodies/ nonspecific 
bands. That can lead to results “false positive”. The negative controls are important 
to rule out this issue in addition to choosing an appropriate blocking solution.  
3.13.2. Homogenate Preparation 
Then samples were sliced in 10 microns by using cryostat sectioning machine (Leica 
CM1950 Leica Biosystems Nussloch GmbH) at -20°C. Tissue Homogenization was 
done in 10 times concentrated volume (e.g. 50l in 5mg) of homogenization buffer 
(20mM Tris base, 250mM sucrose, 1mM  EGTA,1mM EDTA)  to which protease 
inhibitors cocktail and phosphatase  inhibitors were added (Sigma-Aldrich). 
Following homogenization, samples were centrifuged at 1600 rpm for 10 minutes at 
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4°C. The Supernatant was collected in fresh Eppendorf tubes for storage at -80°C 
until use.  
3.13.3. Assessment of protein concentration of samples 
The protein concentration of samples was determined using the bicinchoninic acid 
(BCA) protein assay method (Thermo Scientific, Loughborough, UK).   This assay 
is based on the reduction of Cu
2+
 ions to Cu
+
 by protein in an alkaline medium 
(known as the biuret reaction) and the subsequent reaction of the reduced copper 
cation with BCA to produce a quantifiable colorimetric reaction. 
 
Table 3-2 Antibodies used for Western blot experiments 
 
The colour intensity may be measured via spectrophotometry (wavelength 595nm); 
colour intensity is proportional to protein concentration allowing accurate 
determination of sample protein concentration between ranges of 20 to 2000 µg/ml. 
The BCA assay was conducted in a 96 well plate.  A  series  of  protein (bovine  
serum  albumin  (BSA))  standards  25-2000  µg/ml  were  made  from 2000 µg/ml 
stock diluted in total homogenization buffer. 1:50 dilutions of total homogenate 
were prepared, 50 parts of BCA reagent A (Sodium carbonate, bicinchoninic acid, 
sodium bicarbonate and sodium tartrate in 0.1M sodium hydroxide) was added to 1 
part BCA reagent B (4% cupric sulphate) to form the BCA working reagent. 10l of 
diluted total homogenate sample was added to the microplate in triplicate, 200l of 
BCA working reagent was then added to each well and plates were covered and 
incubated at 37°C. Plates were analysed on a plate reader (Dynex Technologies, 
Worthing, UK) and results recorded. Triplicates were examined, and any values 
greater than +/- 10% were excluded, the value for each sample was taken as the 
average of each triplicate (or duplicate where a value had been excluded). A 
Primary 
antibody 
Species 
Type 
Clone Source Dilution used Secondary antibody 
Akt Rabbit Polyclonal Cell signalling 1:1000 Goat anti- rabbit  
P-Akt Rabbit Polyclonal Cell signalling 1:1000 Goat anti- rabbit  
ERk44/42 Rabbit Polyclonal Sigma- Aldrich 1:1000 Goat anti- rabbit  
P-ERK44/42 Rabbit Polyclonal Cell signalling 1:1000 Goat anti- rabbit  
β-Actin Rabbit Polyclonal Sigma- Aldrich 1:5000 Goat anti- rabbit  
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standard curve was constructed from the values of the known standards, and then the 
protein content of samples was determined via linear regression analysis (Fig. 3.10). 
3.13.4. SDS-Page electrophoresis 
Sodium Dodecyl Sulphate PolyAcrylamide Gel Electrophoresis (SDS-PAGE) 
separates polypeptides based on their electrophoretic mobility. SDS binds proteins 
denaturing their polypeptide backbone and causes the dissociation of hydrogen 
bonds which results in an unfolding of tertiary and secondary structures, SDS also 
confers an overall net negative charge on proteins meaning that they are separated 
solely on size. Samples are prepared in Laemmli buffer which contains 2- 
mercaptoethanol, dithiothreitol (DTT), bromophenol blue and glycerol. 2- 
mercaptoethanol and DTT are reducing agents which reduce inter and 
intramolecular disulphide bonds ensuring proteins remain as linear structures, 
bromophenol blue is added as an indicator dye allowing observation of protein 
migration through the gel, it also makes gel loading easier, glycerol is added to 
increase the density of the sample ensuring it will sink to the bottom of the well 
when loaded. All SDS-Page electrophoresis and Western blotting in studies reported 
in this thesis were conducted using the XCell Surelock mini gel system (Invitrogen, 
Paisley, UK). 
 
Figure 3.9. Example of the standard curve for determining proteinconcentration 
The relative absorbance of BSA standards at 595nm increases with increasing 
concentration of BSA. Linear regression was used to calculate the protein 
concentration of samples of total homogenate utilised for Western blotting 
experiments. 
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Following determination of protein concentration of homogenates, samples 
containing equal amounts of protein were prepared for Western blot analysis. 4x 
laemmli buffer and RIPA buffer were added to each sample to make up to the 
required volume. Samples were heated at 70°C in a water bath for ten mins to 
denature proteins and then vortexed before gel loading protein was separate by SDS-
polyacrylamide gel electrophoresis on 4-12% Bis/ Tris gels using 2-(N-morpholino) 
ethane sulfonic acid (MES) running buffer (Invitrogen, Paisley, UK), gels were run 
for 1.5 – 2 hours at 115 V unless otherwise stated. 
3.13.5. Protein transfer 
After running SDS page, when proteins were separated in the gels, gels were 
removed from the apparatus. By gentle handling, upper gel consist of stacking gel 
was trimmed off and transferred to filter paper soaked with transfer buffer (6cm x8 
cm).  Polyvinylidene fluoride (PVDF) membrane (GE Healthcare, Amerbaseline, 
UK)  was dipped into 100% Methanol and distal water for three and one minute 
respectively, from where membrance and then another layer of soaked filter paper 
was placed over gel.  Blotting paper, membrane, gel and blotting paper „sandwiches‟ 
(Fig 3.11) were adjusted in blot modules (Bio-Rad Laboratories, Inc.). After proper 
securing the blot transfer apparatus with gel sandwich were filled with transfer 
buffer solution with 20% methanol. Protein transfer was done using constant 300 m 
A for the period 2.5 hours.  
 Following protein transfer, membranes were incubated in Ponceau S solution 
(Sigma-Aldrich Company Ltd., Dorset, UK) to ensure equal loading of protein. 
Membranes were then blocked in 10ml Odyssey blocking buffer (Li-Cor 
Biotechnology UK Ltd., Cambridge, UK) / PBS (1:1) in a light proof box at room 
temp for one hour. Membranes were incubated with primary antibody in blocking 
buffer/PBS (1:1), 0.1% Tween20 (Sigma-Aldrich Company Ltd., Dorset, UK) 
solution (10ml) overnight at 4°C.   
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Figure 3.10. Schematic diagram of a filter paper, gel, membrane and filter paper 
“sandwich”.  This was placed between wet sponges soaked in 20% transfer buffer 
solution and into a blotting module, a current was passing through negative toward 
positive plate for protein transfer to PVDF membrane.( Image adapted from a web 
of Darrel J Killian). 
 
 
In Western blot experiments, β-actin (1:5000, Sigma-Aldrich Company Limited, 
Dorset, UK) used as a loading control. On next day, membranes were washed three 
times 5 mins each time in TBS-T (0.1% Tween) solution, then incubation with an 
appropriate secondary antibody (1:10,000 LiCor Biotechnology UK Limited, 
Cambridge, UK) using blocking solution in TBS-T solution for 50 minutes at room 
temperature. Following secondary antibody incubation, membranes were washed 
three times in TBS with 0.1% Tween20 solution for 10 minutes each time. 
Membranes were developed using Synegene Box. Images were saved in Tif. 
Version for quantification. 
 
3.13.6. Quantification of protein levels 
Actin was used as a loading control in all blotting membranes. To confirm the 
reliability of actin as a loading control, actin expression was confirmed in 
myocardial ischemic and reperfusion tissue and results were not influenced by 
ischemia nor reperfusion. Actin protein was also verified in all groups with the 
baseline. 
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3.14. Statistical Analysis 
All statistical analysis was performed using SPSS statistical package (version 
10.0.7). All values were expressed as means  SD of the mean. Hemodynamics, 
apoptosis, and inflammation were compared by using a one-way (ANOVA).A 
Mann-Whitney U test and Student t-test were used for comparison of data between 
baseline, control and treated groups. Correlations between groups were assess using 
the Pearson's correlation coefficient(r). The difference was statistically significant 
considered as a P value ≤ 0.05.
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SECTION III-A 
4. Cardioprotective effect of fingolimod in 
Cardiac Arrest (CA) and ExtraCorporeal Life 
Support (ECLS) resuscitation in experimental 
model 
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4.1. Introduction 
Sudden cardiac arrest is a major cause of mortality in the developed world205 
and post resuscitation mortality remains more than 50%206. CA and 
cardiopulmonary resuscitation both are associated with global myocardial ischemia 
reperfusion injury that induce myocardial dysfunction, leading  to poor prognosis 
and adverse outcome
207
. Currently, ECLS is an effective way to treat cardiogenic 
shock or CA, because of  its great potential to provide a quick circulatory support 
via peripheral vascular access
208
. The sphingosine 1-phosphate (S1P) is known 
lysolipid mediator for more than 2 decades to play a role in cellular changes, 
including differentiation, proliferation, migration, contraction and survival
209-214
.  
Sphingosine 1-phosphate is able to increase the survival of cardiomyocytes during 
episodes of hypoxia; evidence emerged from in vitro studies 
135, 136
, it can also 
reduce the size of the infarcted area in productions of isolated hearts ex vivo and in 
vivo model 
137, 138, 185
. The role of sphingosine 1-phosphate in cytoprotection is 
under debate by its survival pathways activation. However, pharmacological post-
conditioning with sphingosine 1-phosphate activation has been shown for potential 
application after resucitation in in-vitro and in vivo study
215
. Primarily, end points 
for our study were included functional aspects and level of myocardial protection. 
Sphingosine 1-phosphate receptors agonist fingolimod act as a pharmacological 
cardioprotective agent for post CA resuscitation care have not been investigated yet. 
Our hypothesis is that fingolimod play cardioprotective role in global ischemia 
reperfusion related to sudden cardiac arrest. Therefore the aim of this study was to 
assess the cardioprotective effects of S1P receptors activation by fingolimod  after  
resuscitation from CA during ECLS in rat model as compared to control group. To 
understand cardioprotective role of fingolimod, we investigated functional 
hemodynamics parameters, apoptosis, inflammation and Akt and Erk11/2 pathways.  
 
4.2. Methods 
4.2.1. Animals 
Sprague-Dawley Rats (300-350grams) Obtained from Harlan Laboratories (Udine, 
Italy). They were fed standard rat chow, which they had access to ad libitum. Rats 
were housed at a density of 3-4 per cage and maintained on a 12-hour light/dark 
cycle at 21°C. The study was approved by the National Animal Welfare Committee. 
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4.2.2. Experimental design 
At the initiation of ECLS after 10 min of untreated VF, rats were randomly 
categorized into two groups, Group A was treated with normal saline, and in Group 
B, fingolimod administration was done at dosage 1 mg/kg through femoral vein 
cannula. Group C and D were similarly treated with saline and fingolimod 
respectively. In Group A and B, after 1 hour of reperfusion hemodynamic 
measurements were done and myocardial tissue was collected to calculate high 
energy phosphates. During ECLS internal temperature was kept at 36-37°C in both 
groups. While in Group C and D reperfusion were allowed upto 24 hours. In later 
groups, ECLS weaning was done with hemodynamic stabilization and rewarming 
followed by heating lamp. After 24 hours of reperfusion, hemodynamics were 
measured similarly as at 1 hour and blood and myocardial tissue were collected for 
further analysis of inflammation, apoptosis and oxidative stress. Schematic review 
of the experiment is illustrated in Fig. 4.1. 
Experimental techniques, tissue and blood analysis protocol is mentioned in section 
II(Materials and Methods). 
 
Figure. 4.1. Schematic view of experimental study. 
4.3. Results 
4.3.1. Left Ventricular Function 
Baselines hemodynamic were similar in both groups (Table 4.1).  When global 
ischemia through CA was subjected in all rats following fingolimod treatment in 
Group B and D (n=15 each group)  and saline treatment in Group A and C (n=15 in 
each group). Hemodynamic measurements were done to evaluate LV performance 
using the Millar catheter system (Fig. 4.2). 
Table 4-1 Comparison of baseline characteristics among different groups 
Baseline Group A Group B P value Group C Group D P value 
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HR (beats/min) 281±16 278±21 ns 309±29 295±24 ns 
MAP (mmHg) 137±16 132±18 ns 112±14 116±16 ns 
CO (ml/min) 42±3.5 45±4.2 ns 44±3 47±5.2 ns 
 
The LV End Systolic Pressure (LVESP) elevated significantly after CA and 
resuscitation in Group D as compared to Group C (p ≤ 0.05)(Fig. 4.2A). No 
difference between Group A and B were observed (p>0.05).  The LV End Diastolic 
Pressure (LVEDP) measurements showed a reduction in the Group B and D vs. 
Group A and C (p=0.04) (p≤0.05) respectively(Fig. 4.2B).  On the other hand, The 
minimal pressure relaxation rate (dP/dt min) was also improved in Group B and D as 
compared to Group A and Group C (p≤0.05) (Fig. 4. 2C). Ventricular systolic 
performance dp/dt max after CA+reperfusion was increased in Group D vs. Group C 
(p ≤ 0.05) (Fig. 4.2D).  
 
   
85  
 
Figure. 4.2. Hemodynamic parameters measured at baseline, at 1hour and 24 hours of 
reperfusion. Effects of FTY720 on left ventricular function in the rats with a CA-
reperfusion-induced injury. Following 10 mins CA, treatment administered at the start of 
reperfusion, (A) Effects of FTY720 on LVESP. (B) Effects of FTY720 on LVEDP. (C) Effects 
of FTY720 on LV dp/dt min. (D) Effects of FTY720 on LV dP/dt max, LVESP and LVEDP 
were measured using a multichannel physiological recorder. LV dP/dt max and min was 
expressed as mmHg/sec. LVESP and LVEDP were expressed as mmHg. LV dP/dt max, the 
rate of maximum positive left ventricular pressure development; LV dP/dt max, the rate of 
maximum negative left ventricular pressure development; LVESP, left ventricular end-
systolic pressure; LVEDP, left ventricular end-diastolic pressure. Values are expressed as 
the means ± SD.  
4.3.2. Bcl-2 and BAX signaling pathways 
Following 10 min of CA and 24 hours of reperfusion, myocardial tissue was excised 
for immunohistological staining to measure the expression levels of anti-apoptotic 
(Bcl-2) and pro-apoptotic (Bax) proteins. As presented in (Fig. 4.3), in FTY720 
A 
D C 
B 
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treated(Group D) Bcl-2 expression were significantly increased versus CA-control 
group (Group C), while expression of BAX was down-regulated in Group D as 
compared to Group C (P≤0.05), indicating that fingolimod during CA attenuates 
apoptosis by up-regulation of Bcl-2 and downregulation of Bax proteins. 
 
Figure. 4.3. Myocardial tissue expression levels of Bcl-2 and Bax after10 min of CA and 24 
hours reperfusion. The protein expression levels of Bcl-2 and BAX were determined by an 
immunohistochemistry, (A) BAX expression in CA-control group, (B) Bax expression in CA-
FTY720 treated group.(Control vs. Treated p≤0.05) (C) Bcl-2 expression in Control- CA 
group and (D) Bcl-2 expression in FTY720 treated group (Control vs. Treated (p≤0.05)).  
4.3.3. Effect of fingolimod on apoptosis 
TUNEL assay is standard way to assess apoptosis, it shows extensive apoptosis in 
Group C. S1P receptors activation by using fingolimod showed a significant 
attenuation  of TUNEL-positive nuclei in myocardial tissue of cardiac arrest and 
reperfusion, it indicates that fingolimod exert anti-apoptotic role in I/R related to CA 
(Fig.4.4).  
Bcl-2 Bcl-2 
Bax Bax 
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Figure. 4.4.  Representative photomicrographs of immunofluorescent staining for TUNEL-
positive nuclei in the baseline, I/R-control, I/R-Fingolimod groups. (A, D, G) shows only 
DAPI in myocardial tissue, (B, E, H) TUNEL positive signals and (C, F, I) merged images.  
TUNEL-positive myocytes were much lower in numbers frequently in control CA group than 
in CA-FTY720 group. Original magnification 20x. 
4.3.4. Interstitial collagen deposition 
Interstitial collagen deposition measured by collagen volume fraction (CVF), to 
evaluate myocardial fibrosis after VF- induced CA and reperfusion for 24 hours. The 
differences in the interstitial collagen deposition late phase of reperfusion as shown 
in (Fig.4.5). To calculate CVF,  we measured the collagen staining expression (blue) 
in Masson‟s trichrome-stained images.(B) Fingolimod (1mg/kg) treated group 
demonstrated a low level of CVF  as(A) compared to control group in CA (p≤0.05).   
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Figure 4.5. Representative photomicrograph showing the fibrosis in CA induced ischemia-
reperfusion (20xMagnification). FTY720 attenuated post‐ CA myocardial interstitial 
fibrosis. The viable myocardium is stained bright red. Fibrosis is stained bright blue, (A) 
CA without fingolimod (n=15) and (B) CA with fingolimod (1mg/kg) (n=15). 
4.3.5. Fingolimod attenuates neutrophil infiltration 
In CA -I/R group, there were interstitial edema and structural disarray, and including 
neutrophils infiltration observed. However, pre ischemia FTY720 treatment,  
remarkably reduced morphological changes and neutrophil infiltration. Difference 
between control and treated group were statistically significant (p≤0.05)(Fig. 4.6). 
 
Figure 4.6 Representative photomicrograph showing the histopathological changes in CA 
induced ischemia-reperfusion(20X Magnification). A. Cardiac section shows 
interstitial oedema and neutrophil infiltration in control, B, Heart tissue section 
showing mild necrosis and band contractions in fingolimod-treated group. 
4.3.6. Fingolimod reduces Nitrative stress 
Nitrative stress also plays an important role in myocardial tissue injury under 
ischemia-reperfusion. Excessive NO production from NOS and the reaction product 
A 
 
B 
 
A B 
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between NO and peroxynitrite; superoxide, have been observed to activate apoptotic 
signalling pathways leading to apoptotic cell death. To determine whether FTY720 
may reduce myocardial nitrative stress caused by CA related ischemia-reperfusion 
and thus attenuation in myocardial apoptosis, we determined peroxynitrite 
expression. As illustrated in (Fig. 4.7), FTY720 markedly down-regulated 
peroxynitrite expression, that indicates decrease production of nitrotyrosine.  
 
Figure. 4.7. Myocardial nitrotyrosine staining (A) FTY720-Treated group(n=15), 
(B) Control group (n=15), Rats were subjected to 10 mins CA followed by 24 hours 
reperfusion. At the end of the experiment, the heart was removed, and nitrotyrosine 
localization were determined.  
4.3.7. Serum levels of CK-MB and cTnI 
Cardiac markers of cardiomyocyte injury, the serum levels of CK-MB and cTnI 
were 22±9.3 and 5.35±0.60 U/g protein in the baseline-operated group and were 
significantly increased in the CA-reperfusion group to 128.8±10.9 and 21.72±0.99 
U/g protein, respectively. Following treatment with fingolimod the CK-MB and 
cTnI levels were significantly decreased as shown in (Fig.4.10).  
 
Figure. 4.8. Serum Levels of creatine kinase-MB (CK-MB) and cardiac troponin I  (cTnI) in 
the serum of rats in the baseline, CA- reperfusion and CA-reperfusion+Fingolimod 
** ** 
≠ 
≠≠ 
Baseline Baseline 
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group(1mg/kg) groups. all Values were expressed as the means ± SD (n=10). (**P≤0.01 vs. 
baseline; ##P≤0.01 and #P≤0.05 vs. Control group). 
4.3.8. Serum levels of Inflammatory Mediators 
 In comparison with baseline, CA-related I/R injury caused by marked elevation in 
the levels of cytokines level mainly TNF-α, IL-1β, IL-6 and ICAM-1. All these 
cytokines increase in serum in response to ischemia and reperfusion. In present 
study, in CA-reperfusion related I/R injury these mediators have been measured. 
Although, ICAM-1 is independently increased in response to I/R, in CA-related 
ischemia-reperfusion elevation has been observed. Compared to baseline TNF-α, IL-
6, IL-1β and ICAM-1 serum levels were significantly increased in CA-reperfusion 
group (p≤0.001). On administration of fingolimod (1mg/kg) TNF-α, IL-6, 1L-1β and 
ICAM-1 vs. control group attenuated (p≤0.05, p≤0.05, p≤0.05, and p≤0.001) 
respectively as shown in (Fig. 4.9). 
 
 
Figure. 4.9. Myocardial production of TNF-α (A), IL-6 (B) and ICAM-1 (C) and IL-1β (D) 
after 10 min CA and 24 hours of reperfusion, (A) CA model without fingolimod 
treatment shows high expression of TNF-α as compared to fingolimod treatment. 
(B)CA-Reperfusion induced significant high IL-6 after 24 hours of reperfusion 
compared with the fingolimod treated and baseline group, (C) FTY720 treated 
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group remarkably reduced the production of the ICAM-1 as compared to Control 
(D) this section of the panel presents, production of 1L-1β higher in control vs 
FTY720 treated group in CA-reperfusion group. Each bar height represents the 
mean ± SD (each group n=15). 
(
 
##
P ≤ 0.01 vs. baseline. *P ≤ 0.05 and **P ≤ 0.01 
vs. CA-control group). 
 
4.3.9. Effect of fingolimod on Erk1/2 and Akt1/2 signaling pathways 
Pro-survival signalling pathways were measured in the myocardial tissue.Akt/ PI3 
kinase pathway is important survival signalling pathway. We measured the 
phosphorylation level of Akt in Group C and D in the myocardial tissue. As shown 
in (Fig. 4.10A), phosphorylation levels of Akt1/2 increase over control group (P ≤ 
0.05). ERK1/2 phosphorylation were analysed by Western blot in rat myocardial 
samples. As shown in (Fig. 4.10B), phosphorylation level of ERK1/2 increased in 
Group D versus Group C (P ≤ 0.05).  
 
Figure 4.10 Representative Western blot and relative density ratio of the phosphorylated (p) 
form of Akt1/2 (A) ERK1/2 (B), samples of left ventricle at the end of 24hours reperfusion. 
Relative Densities shows Fingolimod activate phosphorylation of these proteins. Values are 
means ± SD; (n =15 samples/group). (*p≤0.05, **p ≤ 0.001). 
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4.3.10. High Energy Phosphates 
The measurement of high-energy phosphates in model of CA and resuscitation 
revealed the superior preservation in myocardium using fingolimod treatment (Fig. 
4.12).  Phosphocreatine, the buffering energy source for ATP in situations of energy 
demand, was significantly higher in the fingolimod administered group of animals 
compared with the control group tissue (P ≤ .01), whereas ATP was significantly 
increased after both the 1 hour and 24 hours of reperfusion in treated group as 
compared with the control group (P ≤ .04). Energy charge was significantly elevated 
after 1 hour of reperfusion in fingolimod treatment group as compared with the 
control group (0.85 ± 0.12 vs 0.63 ± 0.15; P ≤ .05), whereas the after 24 hour 
reperfusion, it was not statistically significant (0.83±0.13)(p>0.05).  
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Figure. 4.10. High-energy phosphates in myocardial tissue of the LV in the fingolimod 
treated groups compared with the control group. ( (A) AMP, ADP and ATP levels at 1 hour 
and 24 hour of reperfusion B) Changes in phosphocreatine , (*p≤0.05, **p≤0.001) AMP, 
Adenosine Monophosphate; ADP, Adenosine DiPhosphate; ATP, Adenosine Tri-Phosphate. 
4.3.11. Oxidative Stress 
To examine whether fingolimod regulates the free radicals production on ischemia-
reperfusion, we examined free oxygen radicals and aldehydes (lipid peroxidation 
derivatives) in the frozen myocardial sample. In CA-control group,  reactive oxygen 
species level found higher as compared to CA-fingolimod treated group.  
Particularly, we analysed free reactive oxygen species and  malondialdehyde in   
myocardial tissue  by chromatography and mass spectrometry. Collectively, our 
results suggest fingolimod treatment in CA decrease oxidative stress (Fig. 4.12).  
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Figure. 4.11. Oxidative stress Comparison of oxidative stress in fingolimod treated and 
control group. ROS. Reactive oxygen species, CA. Cardiac Arrest, FTY720. Fingolimod, 
Carr. Unit. Carratelli Unit. (**p≤0.001,*p≤0.05). 
 
4.4. Discussion 
The cardioprotective strategies to prevent acute global ischemia reperfusion injury 
have been tested with different approaches. During last two decades, ~1000 
experimental studies have been investigated for cardioprotective role  including 
volatile anesthetic agents
216-218
, sodium hydrogen exchange inhibitors
219
, statins
220
, 
pharmacological preconditioning
221, 222
 and anti-inflammatory strategies. Majority of 
the preclinical strategies could not work in clinical settings.  
In this study, administration of fingolimod demonstrated inhibition of apoptosis by 
inhibiting inflammation, oxidative stress and preservation of high energy 
phosphates. In our investigations on molecular and protein level both, 
cardioprotection has been observed. We have also demonstrated inhibition of pro-
apototic and activation of anti-apoptotic proteins, reduction in oxidative and nitrative 
stress, preservation of high energy phosphates. The phosphorylation of Akt1/2 and 
Erk1/2, are important for cell survival pathways 
223-225
, were also investigated in this 
study. 
In literature, many studies suggested cardioprotective role of fingolimod by 
activating survival pathways ex-vivo in mouse and rat hearts and in vivo models
137, 
138
. Recently, a study reported knock-out mice of S1P receptors produced a high 
level of myocardial damage as compared to wild type
179
. In another study, mice with 
the lack of Sphingosine kinases demonstrated a big infraction size as compared to 
control mice. In addition to activation of S1P receptors, metabolism of S1P have 
also significance in pre and post conditioning cardioprotective mechanisms
138, 177, 178, 
226
.  
* ** 
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Ischemia reperfusion injury can be caused by different mechanisms and pathways. 
Activation of apoptotic pathways, complement system activation, increased 
inflammation, and oxidative stress can cause myocardial injury following ischemia 
reperfusion
227
. Fingolimod shows potential to deal with most of the above 
mentioned myocardial damaging mechanisms to prevent I/R injury.  
Reperfusion after transient ischemia in myocardium leads to apoptosis in 
cardiomyocytes and cardiac dysfunction
228, 229
. TUNEL positive nuclei staining i.e. 
standard method to measure level of apoptosis have been used in this study. 
Consistent with the previous results, the rats treated with fingolimod after 10 min of 
CA, expressed a lower frequency of TUNEL positive nuclei after 24 hours of 
reperfusion. It indicates the cardioprotective role of fingolimod by activating anti-
apoptotic cascade.  
S1P receptor agonists have important role in immune suppression
230
. Porcine model 
of I/R
185
 and spontaneous obstructive coronary atherosclerosis murine model
231
, 
tested for immunosuppression, showed reduction in infarct size and mortality in 
fingolimod treated group. We measured inflammation in blood and tissue. In blood, 
we have found significantly low concentration of pro-inflammatory cytokines.  
The ICAM-1, IL-6, IL-1β and TNF-α contribute as a pro-inflammatory cytokines to 
develop inflammatory mechanisms 
232-234
.  The correlation was found between anti-
inflammatory effects of fingolimod on cardioprotection. I/R increased ICAM-1, IL-
6, IL-1β and TNF-α level in control group, whereas fingolimod treatment decreased 
the concentrations of these cytokines. Therefore, the suppression of inflammatory 
cytokines by fingolimod treatment protects myocardium from I/R injury caused by 
pro-inflammatory cytokines.  
One of the main targets of this drug is to mitigate apoptosis in I/R. During I/R, 
molecular signaling RISK and SAFE pathways activation have been reported 
138, 175
. 
The RISK (Akt1/2, Erk1/2 and GSK-3β) and SAFE (JAK and STAT3) pathways are 
main source for mitigation of apoptosis by preventing opening of mitochondrial 
permeability transition pore 
3, 173, 174
. Consistent with the previous findings, 
activation of RISK and SAFE signaling pathways were observed following 
decreased level of apoptosis in treated group as compared to the control. The 
inhibition of pro-apoptotic proteins BAX and enhanced immuno-reaction for anti-
apoptotic protein Bcl-2 were found after 10 min of CA and 24 hours of reperfusion. 
4.6. Conclusion 
In conclusion, fingolimod play important role in preservation of cardiac mechanical 
functions, reduction in myocardial apoptosis, inflammation, oxidative and nitrative 
stress. Furthermore, potential mechanism in cardioprotection is associated with 
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activation of Reperfusion Injury Salvage Kinase and Survivor Activating Factor 
Enhancement pathways.  As a result, hemodynamic parameters improved in late 
phase of reperfusion.   
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SECTION III-B 
5. Cardioprotective effect of Sphingosine 
1-phosphate in Cardioplegic Arrest model 
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5.1 Introduction 
Cardiopulmonary bypass (CPB) assisted open-heart surgery is important for the 
surgeon to perform routine cardiac surgeries in a blood free operating field. 
Cardioplegic arrest (CPA) means heart stops functioning and is separated from 
systemic circulation while protected from ischemic injury by the cardioplegic 
solution. After the unavoidable operating ischemia, immediate myocardial blood 
flow causes reperfusion injury that leads to further myocardial tissue damage
235
. 
Ischemia-reperfusion injury is a consequence of the release of reactive oxygen 
species, inflammatory mediators and apoptosis, which may lead to compromised 
mechanical cardiac function and arrhythmias 
236-238
. The risk of cardiac surgery has 
increased for the last few years especially for  the high-risk patients  undergoing  
complicated  and prolonged cardiac surgical procedures
239
. Various conditions like 
aging, high rate of co-morbidities, redo-operations due to complications, multiples 
procedures, coronary artery bypass grafting (CABG) plus valvular surgeries may be  
categorised as high-risk conditions
240
. These high-risk cardiac surgery patients are 
more susceptible to perioperative reperfusion injury and infarction. These patients 
are usually with multiple co-morbidities and are at a high risk of ischemia-
reperfusion (I/R) injury, acute renal failure
241
 and stroke
242
.   Recent studies have 
demonstrated that other than inflammatory cascade and oxidative stress, nitrative 
stress also plays an important role in I/R-induced myocardial tissue injury
243
. 
Excessive production of nitric oxide (NO) from NOS and its highly reactive 
products such as peroxynitrite and superoxide have been reported to activate several 
apoptotic pathways leading to apoptotic cell death
244
. For the last few decades, the 
role of sphingosine 1-phosphate (S1P)- a derivative of ceramide has been a hot topic 
of discussion for cytoprotection by  causing activation of its survival pathways and  
inhibition of proinflammatory pathways, nitro-oxidative stress and apoptosis.  
Previous studies  have shown the role of  SIP in hibernation  where it also act as a 
key player in mediating effects of hypothermia 
245
. However, pharmacological pre-
conditioning and activation of sphingosine 1-phosphate have shown potential 
application in cardioplegic arrest commonly seen in CABG 
215
. Primarily, end points 
for our study were functional aspects and level of myocardial apoptosis. Sphingosine 
1-phosphate receptors agonist FTY720 might act as potential pharmacological agent 
for cardioprotection. Therefore the aim of this study was to assess the 
cardioprotective effects of S1P receptors activation by FTY720 in the clinical setting 
of cardioplegic arrest in a rat model. To understand the cardioprotective role of 
FTY720, we also aim at investigating Reperfusion Injury Salvage Kinase (RISK) 
and Survivor Activating Factor Enhancement (SAFE) pathways, apoptosis, role of 
inflammatory mediators and oxidative stress  and their relationship with functional 
hemodynamics parameters. 
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5.2. Methods 
5.2.1. Animals 
After  approval from  the institutional Animal Care Committee, 30 male Sprague-
Dawley rats (300-350 grams) were obtained from Harlan Laboratories (Udine, Italy) 
and fed standard rat chow, which they had access ad libitum. The rats were housed 
at a density of 3-4 per cage and maintained on a 12-hour light/dark cycle at 21°C.  
Rats were anesthetized (sodium pentobarbital, 30 mg/kg intraperitoneally) and 
intubated using oropharynx with a 14-gauge polyethylene tube. Mechanical 
ventilation was done with a rodent ventilator (Harvard Apparatus Inc., Holliston, 
Massachusetts). The tidal volume was 6 mL/kg and the respiratory rate was 50 to 
60 breaths/min with an air-oxygen mixture (inspired oxygen fraction = 0.5)246. Rats 
were secured supine on a heating board to maintain rectal temperature at 37°C 
during the surgical procedure before the initiation of cardioplegic arrest. The left 
femoral artery was cannulated with a heparinized 24-gauge Teflon catheter to 
monitor systemic arterial pressure and central cannulation was performed as 
described previously 
247
 . In brief, after complete sternotomy, a venous cannula (a 
modified 4-hole 16-gauge Angiocath catheter) was advanced into the right atrium 
with good drainage.  The left common carotid artery was cannulated using an 18-
gauge catheter advanced to the aortic arch.  
Full heparinization (500 IU/kg) was assured after surgical preparation and 
immediately before cardioplegic arrest initiation to reduce overall blood loss. The 
setup consisted of a venous reservoir, a roller pump, a hollow fiber oxygenator 
(Sorin, Mirandola, Italy), and a vacuum regulator with an applied pressure of 
−30 mm H2O to facilitate venous drainage, all connected by 1.6-mm internal 
diameter plastic tubing. Total priming volume was 10.5 mL, gas exchange surface 
was 450 cm2, and heat exchange surface was 15.8 cm2. 
5.2.2. Experimental design 
In this study,  30  rats were randomized into two groups with 15 animals in each 
group. The first (Group A) was treated with FTY720 1 mg/kg through I/V cannula 
and the second (Group B) was treated with saline to serve as the control group. After 
15 min of both treatments, rats underwent cardioplegic arrest (CPA)  using cold St. 
Thomas solution and aortic clamps for 10 min following initiation of Extra 
Corporeal Life Support (ECLS) for next 1 hour as described in a previous study
247
. 
During ECLS, internal temperature was kept at 36-37°C in both the groups. After 1 
hour of reperfusion, in all rats, ECLS weaning was done and blood and heart tissue 
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were collected for analysis. Schematic review of the experiment is illustrated in 
Figure 1. 
 
 
Figure. 5.1  Schematic view of experimental design. 
 
5.4. Results 
5.4.1. Left ventricular function 
Baseline hemodynamics was similar in both groups (Table 1).  No significant 
difference was observed in Groups A and B.  Hemodynamic measurements were 
done to evaluate LV performance using the Millar catheter system in both groups at 
baseline and after 1 hour of reperfusion (Figure 2).  
Table 1. Comparison of baseline hemodynamics in Group A and Group B. 
Variables 
Group A 
(treated) 
N=15 
Group B 
(control) 
N=15 
p-value 
HR  /min    370 326 Ns* 
MAP mmHg   130 129 Ns 
LVESP  mmHg 95,2 92,2 NS 
LVEDP mmHg  8,2 8,0 Ns 
dP/dt max mmHg/s   7305 7427 Ns 
dP/dt min mmHg/s   7672 7511 Ns 
*Ns denotes not significant 
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The LV end systolic pressure (LVESP) was improved after 1 hour but statistically 
did not reach the level of significance (p=0.06). The LV end-diastolic pressure 
(LVEDP) measurements showed a reduction after 1 hour of reperfusion in the 
treated vs. control group (p=0.03).  Ventricular systolic performance dP/dt max after 
CPB was improved as in the FTY720-treated vs. control group but didn‟t reach 
statistically significance (p=0.2).On the other hand, the minimal pressure relaxation 
rate (dP/dt min) was significantly lower in  the control group compared to the treated 
group (p=0.02).  
 
Figure 5.2:  Hemodynamic parameters measured at baseline and 1 hour after 
reperfusion. Effects of FTY720 on left ventricular function in the rats with CPA- 
reperfusion-induced injury. Treatment (FTY720 or saline) was done 15 min prior to 
cardioplegic arrest, (A) Effects of FTY720 on LVESP. (B) Effects of FTY720 on 
LVEDP. (C) Effects of FTY720 on LV dp/dt max. (D) Effects of FTY720 on LV dP/dt 
min, LVESP and LVEDP were measured using a multichannel physiological 
recorder. LV dP/dt max and min was expressed as mmHg/sec. LVESP and LVEDP 
were expressed as mmHg. LV dP/dt max, the rate of maximum positive left 
ventricular pressure development; LV dP/dt max, the rate of maximum negative left 
ventricular pressure development; LVESP, left ventricular end-systolic pressure; 
LVEDP, left ventricular end-diastolic pressure. Values are expressed as the means ± 
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SD,(n=15 in each group). ( #p ≤ 0.01 vs. baseline. *p ≤ 0.05 vs. CPA-control group, 
NS –not significant). 
5.4.2. Serum levels of inflammatory mediators 
Inflammatory mediators have been described to contribute to the CPA-Reperfusion 
related I/R injury
248
. In the present study, serums levels of some of the inflammatory 
mediators in CPA-reperfusion related I/R injury were measured. Although, ICAM-1 
is independently increased in response to I/R, yet in CPA-related ischemia-
reperfusion elevation in its level has been observed. Compared to baseline TNF-α, 
IL-6, IL-1β, and ICAM-1 serum levels were significantly increased in CPA-
reperfusion group (p≤0001). Upon  administration of FTY720 (1mg/kg), levels of 
TNF-α, IL-6, 1L-1β, and ICAM-1  in the treated group were significantly decreased 
as compared to the control group (p≤0.001, p=0.04, p=0.01, and p=0.001, 
respectively) as shown in Figure 5.3. 
 
Figure 5.3: Myocardial production of TNF-α (A)  IL-6 (B) and ICAM-1 (C) and IL-
1β (D), (A) CPA model without FTY720 treatment shows high expression of TNF-α 
as compared to FTY720 treatment. (B) CPA-Reperfusion induced significant high 
ICAM- after 1 hour of reperfusion compared with the FTY720-treated and baseline, 
(C) FTY720 treated group remarkably reduced the production of the ICAM-1 as 
compared to Control (D) this section of the panel presents, production of 1L-1β 
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higher in control vs. FTY720 treated group in CPA-reperfusion group. Each bar 
height represents the mean ± SD (each group n=15). (#p≤ 0.05 and ##p ≤ 0.01 vs. 
baseline. *p ≤ 0.05 and **p ≤ 0.01 vs. CPA-control group). 
 
5.4.3. Nitro-oxidative stress 
To examine whether FTY720 regulates the free radicals production on ischemia-
reperfusion, we quantitated free radicals and aldehydes (lipid peroxidation derivatives) in 
the frozen perfused myocardial samples. In CPA control group, reactive oxygen species and 
malondialdehyde levels were found to be higher as compared to CPA-FTY720 treated 
group.  . Collectively, our results suggest FTY720 treatment in CPA decreased oxidative 
stress (Figure 4 A & B).  
 
 
Figure 5.4:  Oxidative stress Comparison of oxidative and nitrosative stress in 
FTY720-treated and control group in cardiopulmonary bypass model with CPA(A & 
B). ROS. Reactive oxygen species; FTY720. FTY720; Carr. Unit. Carratelli Unit. 
(**p≤0.001,*p≤0.05). Myocardial nitrotyrosine staining (C) FTY720-Treated group, 
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(D) control group (n=15), Rats were subjected to 10 mins CPA followed by 1-hour 
reperfusion.  
In order to investigate whether S1P receptor agonist-mediated attenuation of cardiac 
cell apoptosis is mediated via reduction in reactive nitrogen species, generation of 
peroxynitrites was analyzed by measuring the nitrosylation of cardiac proteins using 
an antibody against nitrotyrosine. As illustrated in Figure 4 C& D, treatment with 
FTY720 markedly reduced the nitrotyrosine protein content, an indicative of 
reduced peroxynitrite generation. 
5.4.4. Effect of FTY720 on Erk1/2 and Akt1/2 signaling pathways 
Activation of pro-survival signaling pathways (MEK/ERK and PI3K/Akt) was analyzed by 
measuring the phosphorylation state of ERK1/2 and Akt by Western blot analyses. As 
shown in Figure 5, the phosphorylation levels of ERK1/2 and Akt were increased in treated 
group (n=15) compared to the control group (n=15) with p ≤ 0.001 and p= 0.04, 
respectively. 
 
Figure 5 Representative Western blot and relative density ratio of the phosphorylated (p) form of 
Akt1/2 (A) ERK1/2 (B), samples of left ventricle at the 1 hour reperfusion. Relative Densities shows 
FTY720 activate phosphorylation of these proteins. Values are means ± SD; (n =15 samples/group). 
(*p≤0.05, **p ≤ 0.001). 
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5.4.5. Bcl-2 and BAX signaling pathways 
Following 10 min of CPA and 1 hour of reperfusion, heart tissue was removed for 
immunohistochemical staining to measure the expression levels of anti-apoptotic 
protein, Bcl-2, and its regulator Bax protein. As depicted in Figure 6, in the FTY720 
treated group, Bcl-2 expression was significantly increased in CPA related I/R 
group, while expression of BAX was down regulated (p=0.02), indicating that 
FTY720 during global ischemia-reperfusion attenuates apoptosis by up-regulation of 
Bcl-2 and down-regulation of Bax proteins. 
 
Figure. 6:The protein expression levels of Bcl-2 and BAX in myocardial tissue were 
determined by an immunohistochemistry, A. BAX expression in CPA-control group, 
(B) Bax expression in CPA-FTY720 treated group.(Control vs. Treated p≤0.05) (C) 
Bcl-2 expression in Control- CPA group and (D) Bcl-2 expression in FTY720 
treated group. (Control vs. Treated p≤0.01) 
 5.4.6. High energy phosphates 
The measurement of high-energy phosphates in model of CPA revealed superior 
preservation of FTY720-treated myocardium (Figure 7A & B). AMP decreased in 
treated group, whereas ADP and ATP were significantly increased after 1 hour of 
   
106  
reperfusion in  the treated group as compared with the control group (p= 0.03) 
(Figure 7A). Phosphocreatine, the buffering energy source for ATP in situations of 
energy demand, was significantly higher in the FTY720 administered group of 
animals compared to the control group (p=0.01) (Figure 7B). 
 
Figure 7: High-energy phosphates in myocardial tissue of the LV in the FTY720-
treated groups compared with the control group. (A) AMP, ADP and ATP levels 
after 1 hour of reperfusion in CPA, (B) Changes in phosphocreatine. (*p≤0.05, 
**p≤0.001) AMP, Adenosine Mono Phosphate; ADP, Adenosine Di Phosphate; 
ATP, adenosine triphosphate. 
5.4.7. Effect of FTY720 on apoptosis 
Tissue apoptosis was analyzed by TUNEL assay. As shown in Figure 8, extensive 
apoptosis was observed after CPA-I/R injury. S1P receptor agonist FTY720 caused 
a significant attenuation of TUNEL-positive nuclei in the myocardium indicating 
reduced apoptosis in myocardial cells (Figure 8).  
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Figure 5.8: Representative photomicrographs of immunofluorescent staining for 
TUNEL-positive nuclei in the negative control, I/R-control, and I/R-FTY720 groups. 
(A, D, G) shows only DAPI in myocardial tissue, (B, E, H) TUNEL positive signals 
and (C, F, I) merged images.  TUNEL-positive myocytes were much lower in 
numbers frequently in control CPA group than in CPA-FTY720 group.CPA, 
CardioPlegic Arrest,  Original magnification 20x. 
5.4.8. Effect of FTY720 on neutrophil infiltration 
In CPA related I/R, development of interstitial edema, structural disarray, and 
neutrophil infiltration was observed. However, pre-ischemia FTY720 treatment 
remarkably reduced morphological changes and neutrophil infiltration. In treated 
group, edema was also attenuated. The difference between control and treated group 
was statistically significant (p=0.03) indicating that FTY720 attenuates infiltration 
of neutrophils (Figure 9). 
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Figure 5.9: Representative photomicrograph showing the histopathological changes 
in rats’ myocardium related to CPA-induced ischemia-reperfusion (20X 
Magnification). A. The cardiac section shows interstitial edema and neutrophil 
infiltration in control group of CPA rat model; B. Heart tissue section showing mild 
necrosis and band contractions in the FTY720-treated group. 
5.6. Discussion 
The pharmacological cardioprotective strategy to prevent acute global I/R injury has 
been tested using different approaches. Over the last few years, multiple 
pharmacological agents including volatile anesthetic agents 
216-218
, sodium hydrogen 
exchange inhibitors
219
,and statins
220
, pharmacological preconditioning 
221, 222
, and 
anti-inflammatory strategies have been explored as potential cardioprotective 
therapies.  However,  majority of preclinical strategies showing cardioprotective 
effects did not work in clinical settings
249
. 
In the present study, administration of FTY720 demonstrated inhibition of apoptosis 
by inhibiting inflammation and oxidative stress. In order to unravel the possible  
molecular mechanism involved in cardioprotectiondue to FTY720, we have been 
able to show activation of RISK and SAFE pathways, in addition to inhibition of 
pro-apoptotic and activation of anti-apoptotic proteins. Akt1/2 and Erk1/2 
phosphorylation investigated in this study is an  important  component of  cell 
survival pathways 
223-225
. 
Previous studies suggested a cardioprotective role of FTY720 by activating survival 
pathways in in vitro, ex vivo in mouse and rat hearts and in vivo animal models 
137, 
138
. In a study, Means et al. reported that knock-out mice of S1P receptors produced 
a high level of myocardial damage as compared to wild type
179
. Moreover, mice 
with a lack of sphingosine kinases were found to have large infraction size compared 
to control mice. In addition to activation of S1P receptors, metabolism of S1P has 
also significance in pre and post conditioning cardioprotective mechanisms 
138, 177, 
178, 226
.  
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 I/R injury can be caused by various mechanisms and pathways. Activation of 
apoptotic pathways, complement system activation, increased inflammation, and 
oxidative stress can cause myocardial injury following ischemia-reperfusion
227
. 
FTY720 shows a potential to deal with most of the myocardial damaging 
mechanisms to prevent I/R injury.  
According to literature, S1P receptor agonists have an important role in immune 
suppression 
230
. Different models have been tested for immunosuppression including 
a porcine model of I/R 
185
, and spontaneous obstructive coronary atherosclerosis 
murine model 
231
. Through these models, a reduction in infarct size and mortality 
has been shown in the FTY720-treated group. We measured inflammatory markers 
in blood and in heart tissue. In blood, we found a significantly low concentration of 
neutrophils, lymphocytes, and pro-inflammatory cytokines.  
The ICAM-1, IL-6, IL-1β and TNF-α as pro-inflammatory cytokines contribute to 
develop inflammatory mechanisms 
232-234
.   . I/R increased ICAM-1, IL-6, IL-1β and 
TNF-α levels in control group, whereas FTY720 treatment decreased the 
concentrations of these cytokines. Therefore, the suppression of inflammatory 
cytokines by FTY720 treatment protects myocardium from I/R injury normally 
caused by these proinflammatory cytokines.  
One of the main strategies for cardioprotection is to mitigate apoptosis in I/R. 
Molecular signaling RISK and SAFE pathways activation have been reported during 
I/R 
138, 175
. The RISK (Akt1/2, Erk1/2, and GSK 3β) and SAFE pathways (JAK and 
STAT3) are the main sources for mitigation of apoptosis by preventing opening of 
mitochondrial permeability transition pores
3, 173, 174
. Consistent with previous 
findings, activation of RISK and SAFE signaling pathways was observed along with 
decreased level of apoptosis in the treated group as compared to the control group. 
This was further supported by decreased activation of pro-apoptotic proteins BAX 
and enhanced  expression of anti-apoptotic proteins Bcl-2 after 10 min of CPA and 1 
hour of reperfusion. 
Reperfusion after transient ischemia in myocardium leads to cardiomyocytes 
apoptosis and cardiac dysfunction
228, 229
. Consistent with previous reports,our 
TUNEL assay results showed that those rats treated with FTY720 15 min before 
CPA, expressed a lower frequency of TUNEL positive nuclei after 1 hour of 
reperfusion. This observation along with above mentioned findings is indicative of 
cardioprotective role of FTY720 by activating anti-apoptotic cascade.  
This study was not without limitations. Coronary artery disease in patients 
undergoing cardiac surgery is mostly associated with multiple co-morbidities 
including diabetes, hypertension and hyperlipidemia. Our experimental model did 
not truly reflect those conditions. Perhaps, this could be the reason that many studies 
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on experimental models failed to show their beneficial effects inactual clinical 
practice. However, in a recent study we have shown that the rat model due to 
similarities in the SIP receptors between rat and human heart would be more 
appropriate to study the beneficial effects of FTY720 in clinical trials. 
In our study, reperfusion time was one hour and we could not study the effect of 
FTY720 in late phase. Prolonged reperfusion could have provided more strong 
evidence of reduction in I/R injury. The effect of FTY720 in structural remodeling 
can be studied only if  there is prolonged reperfusion time.  However,due to complex  
surgical procedure,  it was hard to achieve in our model.  
Furthermore, we administered only one dose before initiating ischemia in our model. 
There is a possibility that multiple doses of FTY720 could offer better 
cardioprotection. This would need further investigation. 
In spite of these limitations, this study did provide evidence that FTY720 has a great 
potential to be used for cardioprotection in cardioplegic arrest.  On the basis of these 
results, it can be suggested that sphingosine 1-phosphate receptor activation in 
patients undergoing cardioplegic arrest during cardiac surgery could be    most 
important  for assessment of the potential clinical efficacy of this cardioprotective  
agent. 
5.7. Conclusion 
In conclusion, FTY720 preserves, high energy phosphates and cardiac mechanical 
functions, and attenuates myocardial apoptosis, inflammation and oxidative stress. 
Furthermore, a cardioprotective mechanism appears to be associated with 
phosphorylation of Akt and Erk1/2 pro-survival cell signaling pathways (RISK and 
SAFE pathways) to prevent myocardial damage. In our experimental setting, at early 
phase no improvement in hemodynamic parameters was observed. Moreover, the 
question of whether a lower dose of FTY720 in human will bring protective effects 
on myocardium needs to be addressed in future studies. 
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SECTION III-C 
6. Cardioprotective role of fingolimod 
(FTY720) in heterotopic heart 
transplantation 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.1. Introduction 
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Heart transplantation is the ultimate treatment option for heart failure
238
. Heart 
Failure (HF) is a major health problem worldwide, with a prevalence of 23 million 
worldwide and 5.8 million alone in the USA
239
. Since 1997, HF has been singled out 
as an emerging epidemic in the world with higher morbidity and mortality in 65 and 
elders
240
. Most common cause of cardiac dysfunction and mortality in cardiac 
transplant patients is due to ischemia-reperfusion injury
241, 242
. Ex-vivo organ 
transportation is the major factor involved in prolonged ischemia and exacerbation 
reperfusion injury that cause major post-operative morbidity and mortality. Factors 
like advanced donor age, smoking, diabetes, prolonged ischemia time also influence 
ischemia reperfusion injury that is the main cause of early graft dysfunction. 
Ischemia/reperfusion injury is correlated with advanced donor age, prolonged 
preservation time, impaired myocardial reserves, is a major cause of primary graft 
dysfunction
243
.   Currently, low potassium solutions give some positive evidence for 
better cardiac graft preservation 
244
. Although low potassium solutions demonstrated 
attenuation of grafted heart damage related to cold storage and ischemia-reperfusion 
injury. But it has been observed that this solution is not sufficient to protect 
myocardial damage due to decreased cellular energy reserves, release of oxidants, 
myocardial stunning and myocardial dysfunction. Till now, there is no efficient 
strategy for cardioprotection during heart procurement and transplantation. To 
achieve optimal cardio protection, other strategies needed to investigate. 
Sphingosine 1-phosphate agonist fingolimod is phosphorylated form of sphingosine 
that is derivative of ceramide may also take part in cardioprotection in heart 
transplantation related I/R injury 
245
. Fingolimod has potent anti-inflammatory and 
anti-oxidant properties that inhibit oxygen free radical
246
. Fingolimod activates 
RISK and SAFE pathways leading to inhibition of pro-apoptotic proteins and 
activation of anti-apoptotic proteins
247
. We hypothesized that fingolimod pre-
conditioning might achieve optimal cardioprotection with its known anti-apoptotic, 
anti-inflammatory and pro-survival pathways activation. In Rat heterotopic heart 
transplantation model, our aim is to investigate the cardioprotective role of 
fingolimod on apoptosis, inflammation, oxidative stress, nitrative stress and 
activation of Akt and ERK1/2 signalling pathways.  
6.2. Materials and Methods 
6.2.1. Animals 
Sprague-Dawley Rats (300-350grams) Obtained from Harlan Laboratories (Udine, 
Italy). They were fed standard rat chow, which they had access to ad libitum. Rats 
were housed at a density of 4-6 per cage and maintained on a 12-hour light/dark 
cycle at 21°C. These rats were used as donors and recipients. The study was 
approved by the National Animal Welfare Committee. 
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6.2.2. Experimental design 
In this study, we used four transplant groups, two for control and two for fingolimod 
treatment 1-hour reperfusion and 24-hour reperfusion respectively, (n=15 for each 
group). Treatment was administered 15 mins before explantation. Intravenous 
injection was given, either fingolimod 1mg/kg (treated) or saline (control group). 
This dose was given on the basis of a previously reported in-vivo study reported by 
Santos-Gallego et al
185
. In Group A (control) and Group B (treated), hemodynamic 
measurement for systolic and diastolic function was performed after 1 hour of 
reperfusion. In next two groups, Group C (control) and Group D (treated), after 
performing transplantation, abdominal cavity was closed and animals were allowed 
to recover for 24 hours. Following 24 hours of reperfusion with similar environment 
and diet for all animals, again hemodynamic measurements were performed, blood 
and tissue were collected for cardiac, inflammatory, apoptotic, oxidative markers 
and high energy phosphates.  
Experimental techniques, data acquisition and analysis methods are mentioned in 
Section II(methods and materials).  
 
Figure 6.1. Schematic view of experimental design.  
6.3. Results 
 6.3.1. Left Ventricular Function 
Baseline hemodynamics were similar in both groups (Table 6.1).  In all groups, rats 
underwent cardioplegic arrest, explantation, and implantation of the graft. The 
hemodynamics were measured after 1 hour of reperfusion in Group A and B (n=15  
in each)  and after 24 hours of reperfusion in Group C and D(n=15 in each group). 
Hemodynamic measurements were done to evaluate LV performance using the 
Millar catheter system (Fig. 5.B).  
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Table 0-1 Comparison of baseline hemodynamics in Group A vs. Group B and 
Group C vs. Group D. 
Baseline Group A Group B P value Group C Group D P value 
HR (beats/min) 289±17 288±22 ns 309±29 297±17 ns 
MAP (mmHg) 127±15 130±17 ns 112±14 115±11 ns 
CO (ml/min) 43±3 47±5 ns 44±3 50±4 ns 
 
The LV End Systolic Pressure (LVESP) elevated significantly after HT and 
resuscitation in Group D as compared to Group C (P ≤ 0.05)(Fig. 6.2A). No 
difference between Group A and B were statistically not significant.  The LV End 
Diastolic Pressure (LVEDP) measurements showed a reduction in the Group B and 
D vs. Group A and C (p>0.05)(p≤0.05) respectively(Fig. 6.2B).  While, Ventricular 
systolic performance dp/dt max after HT+reperfusion was increased in Group A vs. 
Group B, Group D vs. Group C (P≤0.05)(P ≤ 0.001) respectively(Fig. 6.2C).The 
minimal pressure relaxation rate (dP/dt min) was also improved in Group B and D as 
compared to Group A and Group C (P≤0.05)(Fig. 6. 2D).  
 
Figure 6.2. Hemodynamic parameters demonstration, at 1hour and 24 hours of 
reperfusion. Effects of FTY720 on left ventricular function in the rats with heterotopic 
transplantation. Treatment was given 15 mins prior to explantation of heart, (A) Effects of 
FTY720 on LVESP. (B) Effects of FTY720 on LVEDP. (C) Effects of FTY720 on LV dp/dt 
max. (D) Effects of FTY720 on LV dP/dt min, LVESP and LVEDP were measured using a 
*
* 
*
* 
*
* 
**
* 
*
* 
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multichannel physiological recorder. LV dP/dt max and min was expressed as mmHg/sec. 
LVESP and LVEDP were expressed as mmHg. LV dP/dt max, the rate of maximum positive 
left ventricular pressure development; LV dP/dt max, the rate of maximum negative left 
ventricular pressure development; LVESP, left ventricular end-systolic pressure; LVEDP, 
left ventricular end-diastolic pressure. Values are expressed as the means ± SD.  
6.3.2. Bcl-2 and BAX signaling pathways 
After 24 hours of reperfusion in HT models, heart tissue was excised for 
immunohistological staining to measure the expression levels of anti-apoptotic (Bcl-
2) and pro-apoptotic (Bax) proteins. As presented in (Fig. 6.3), in FTY720, treated 
(Group D) Bcl-2 expression were significantly increased versus HT control 
group(Group C), while expression of BAX was downregulated in Group D as 
compared to Group C (P≤0.05), indicating that Fingolimod during HT attenuates 
apoptosis by upregulation of Bcl-2 and downregulation of Bax proteins. 
 
 
Figure 6.3. Myocardial tissue expression levels of Bcl-2 and Bax after 30-40mins ischemia 
and 24 reperfusion. The protein expression levels of Bcl-2 and BAX were determined by an 
immunohistochemistry, (A) BAX expression in HT-control group(Group C), (B) Bax 
expression in HT+FTY720 treated group(Group D).(Control vs. Treated p≤0.05) (C) Bcl-2 
expression in Group C and (D) Bcl-2 expression in Group D. (Control vs. Treated p≤0.05). 
Bcl-2 Bcl-2 
Bax Bax 
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6.3.3. Effect of fingolimod on apoptosis 
TUNEL assay is apoptosis detection marker, its shows extensive apoptosis in HT-
related I/R injury. S1P receptors activation by using fingolimod showed a significant 
attenuation  of TUNEL-positive nuclei in myocardium, that is indicates anti-
apoptotic effect of fingolimod on myocardial cells apoptosis (Fig.6.4).  
 
Figure 0.4. Representative photomicrographs of immunofluorescent staining for TUNEL-
positive nuclei in baseline, HT-control, HT-Fingolimod groups(Group C and D). (A, D, G) 
Shows only DAPI in myocardial tissue, (B, E, H) TUNEL signals and (C, F, I) merged 
images.  TUNEL-positive myocytes were much lower in numbers frequently in control HT 
group than in HT-FTY720 group. Original magnification 20x. 
6.3.4. Interstitial collagen deposition 
Interstitial collagen deposition measured by collagen volume fraction (CVF), to 
evaluate myocardial fibrosis after HT(60 min ischemia) and reperfusion for 24 
hours. The differences in the interstitial collagen deposition in HT group and 
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HT+FTY720 group as showm in (Fig.6.5). To calculate CVF,  we measured the 
collagen staining expression (blue) in Masson‟s trichrome-stained images. 
Fingolimod (1mg/kg) treated group demonstrated low level of CVF  as compared to 
control group (p≤0.05).  
 
Figure 6.5. Representative photomicrograph showing the collagen deposition in rats 
related to HT ischemia-reperfusion injury (20X Magnification). FTY720 decreased 
post‐HT myocardial interstitial fibrosis. The viable myocardium is stained bright red. 
Fibrosis is stained bright blue. A; HT without fingolimod(n=15) and B; HT with 
fingolimod (1mg/kg)(n=15). 
6.3.5. Fingolimod attenuates neutrophil infiltration 
In HT animals group, there were interstitial edema and structural disarray, and 
including neutrophils infiltration observed. However, pre-ischemia FTY720 
treatment, remarkably reduced morphological changes and neutrophil infiltration. 
Difference between control and treated group were statistically significant 
(p≤0.05). 
A B 
   
118  
 
Figure 6.6. Representative photomicrograph showing the histopathological changes in 
rats related to HT related ischemia-reperfusion (20X Magnification); A. Cardiac section 
shows interstitial oedema and neutrophil infiltration in control group(Group C) in HT 
model; B. Heart tissue section showing mild necrosis and band contractions in 
fingolimod-treated group(Group D). 
6.3.6. Fingolimod reduces Nitrative stress 
Recent studies have demonstrated that other then oxidative stress, nitrative stress 
also plays a important role in myocardial tissue injury under a ischemia-
reperfusion. Excessive NO production from NOS and the reaction product 
between NO and peroxynitrite, superoxide have been observed to activate 
apoptotic signallling pathways leading to apoptotic cell death. To determine 
whether FTY720may reduce myocardial nitrative stress caused by HT related 
ischemia reperfusion and thus attenuation in myocardial apoptosis, we determined 
peroxynitrite  expression. As illustrated in (Fig. 6.7), FTY720 markedly down-
regulated peroxynitrite expression, that indicates decrease  production of nitro-
tyrosine.  
 
Figure 6.7. Myocardial nitrotyrosine staining  (A) FTY720-Treated group(n=15), (B) 
Control group (n=15), Rats were subjected to 60 mins ischemia followed by 24 hour 
reperfusion. At the end of the experiment, the heart was excised, and nitrotyrosine 
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Figure 6.8. Serum Levels of creatine kinase-MB (CK-MB) and cardiac troponin I (cTnI) in 
the serum at the baseline, HT- reperfusion and HT-reperfusion+Fingolimod group(1mg/kg). 
All Values are expressed as the means ± SD (15 rats in each group). (**P≤0.01 vs. 
baseline; #P≤0.05 vs. Control group). 
6.3.8. Serum levels of Inflammatory Mediators 
The inflammatory mediators contribution were identified in the  HT related I/R 
injury. HT-related I/R injury caused by marked elevation in the levels of cytokines 
mainly TNF-α, IL-1β, IL-6 and ICAM-1. All these cytokines increase in serum in 
response to ischemia and reperfusion. In the present study, serum levels of these 
mediators have been measured in HT animals after 24 hours of reperfusion. 
Compared to the baseline TNF-α, IL-6, IL-1β and ICAM-1 serum levels were 
significantly increased in HT-reperfusion group. On administration of fingolimod 
(1mg/kg) TNF-α, IL-6, 1L-1β and ICAM-1 attenuated vs. control group (p≤0.05, 
p≤0.05, p≤0.05, and p≤0.001) respectively as shown in (Fig. 6.9).  
localisation was determined.  
6.3.7. Serum levels of CK-MB and cTnI 
Cardiac markers of cardiomyocyte injury, the serum levels of CK-MB and cTnI 
were 14±8.2 and 3.22±0.52 U/g protein in the baseline-operated group and were 
significantly increased in the HT group to 148.8±8.9 and 26.5±0.69 U/g protein, 
respectively. Following treatment with fingolimod the CK-MB and cTnI levels 
were significantly decreased (P≤0.01 and P≤0.05 vs. control HT-group) as shown 
in (Fig. 6.8).  
 ** 
 **  ≠    ≠ 
Baseline Baseline 
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Figure 6.9.  Myocardial production of TNF-α (A), IL-6 (B) and ICAM-1 (C) and IL-1β (D) 
after 24 hours of reperfusion, (A) HT model without fingolimod treatment shows high 
expression of TNF-α as compared to fingolimod treatment. (B)HT-Reperfusion induced 
significant high IL-6 after 24 hours of reperfusion compared with the fingolimod treated 
and baseline, (C) FTY720 treated group remarkably reduced the production of the ICAM-1 
release as compared to Control (D) this section of the panel presents, production of 1L-1β 
higher in control vs. FTY720 treated group in HT-reperfusion group. Each bar height 
represents the mean ± SD (each group n=6).  (
##
P ≤ 0.01 vs. baseline. *P ≤ 0.05 and 
**P ≤ 0.01 vs. HT-control group). 
 
6.3.9. Effect of fingolimod on Erk1/2 and Akt1/2 signalling pathways 
Pro-survival signalling pathways were measured in the myocardial tissue.Akt/ PI3 
kinase pathway is important survival signalling pathway. We measured the 
phosphorylation level of Akt in Group C and D in the myocardial tissue. As shown 
in (Fig. 6.10A), phosphorylation levels of Akt1/2 increase over control group (P ≤ 
0.05). ERK1/2 phosphorylation were analysed by Western blot in rat myocardial 
samples. As shown in (Fig. 6.10B), phosphorylation level of ERK1/2 increased in 
Group D versus Group C (P ≤ 0.05).  
≠≠ 
≠≠ 
≠≠ 
≠≠ 
** 
 * 
* 
* 
Baseline 
Baseline Baseline 
Baseline 
A 
D C 
B 
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Figure 6.10 Representative Western blot and relative density of the phosphorylated (p) form 
of Akt1/2 (A) ERK1/2 (B), samples of the left ventricle at the end of reperfusion. Relative 
Densities shows Fingolimod activate phosphorylation of these proteins. Values are means ± 
SD. (*p≤0.05, **P ≤ 0.05). 
6.3.10. High Energy Phosphates 
The measurement of high-energy phosphates in model of heterotopic transplantation 
revealed the superior preservation of fingolimod treated myocardium (Fig. 6.11).    
Phosphocreatine, the buffering energy source for ATP in situations of energy 
demand, was significantly higher in the fingolimod administered group of animals 
compared with the control group tissue (P ≤ 0.05). While high energy phosphates 
(AMP, ADP, and ATP) were significantly increased after both the 1 hour and 24 
hours of reperfusion in treated group as compared to the control group (P ≤ 0.05). 
Energy charge was significantly elevated after 1 hour of reperfusion in Group B 
versus Group A (0.79 ± 0.02 vs. 0.71 ± 0.01) ;( P ≤ 0.001), whereas the after 24 hour 
reperfusion, it was not statistically significant (0.78±0.01) (p>0.05).  
** * 
A B 
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Figure 6.11. High-energy phosphates in myocardial tissue of the LV in the fingolimod  
treated groups compared with the control group. (A) Changes in phosphocreatine , (B) ATP 
levels at 1 hour and 24 hour of reperfusion energy charge. (*p≤0.05, **p≤0.005) AMP, 
Adenosine MonoPhosphate; ADP, Adenosine DiPhospahte; ATP, adenosine triphosphate. 
6.3.11. Oxidative Stress 
To examine whether fingolimod regulates the free radicals production in ischemia-
reperfusion, we examined free radicals and aldehydes (lipid peroxidation 
derivatives) in the frozen perfused myocardial sample. In Group C, reactive oxygen 
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species level found higher as compared to Group D.  Particularly, we analyzed free 
reactive oxygen species and malondialdehyde in HT animals myocardial tissue  by 
chromatography and mass spectrometry. Collectively, our results suggest fingolimod 
treatment in HT decrease oxidative stress (Fig.6.12).  
 
Figure 6.12 Oxidative Stress Comparison of oxidative stress in heterotopic transplantation 
model with and without fingolimod treatment. ROS. Reactive oxygen species; HT. 
Heterotopic Transplantation; FTY720. Fingolimod; Carr. Unit. Carratelli Unit. 
(**p≤0.001,*p≤0.05). 
6.4. Discussion 
In this study, we investigated cardioprotective effect of prolonged organ 
preservation during in vivo heart transplantation model. We found that fingolimod, 
efficiently works as ischemic preconditioning agent. Fingolimod improved 
myocardial function as compared to control group after 60 min global ischemia in 
St. Thomas solution and 24 hours of reperfusion. Our findings suggested that 
fingolimod plays an important role in the reduction of apoptosis, inflammation and 
improve mechanical function of the heart.To our knowledge, the present study is 
first to investigate cardioprotective role of S1P receptor agonist in preclinical heart 
transplantation model. 
Fingolimod is one of the most best treatment option in prevention of multiple 
sclerosis relapse. In addition to its immune-modulating effect, fingolimod has a 
number of additional useful actions, including anti-inflammatory, anti-apoptotic, 
anti-oxidative and anti-nitrative stress
248
. These properties are predicted to improve 
the myocardial insult related to ischemia-reperfusion during heart transplantation. 
Previous studies have reported that pretreatment with S1P receptor agonist protected 
myocardium from ischemia/reperfusion injury
249
. In this experiment, we found that 
fingolimod treatment remarkably elevated LVESP and LVEF at late phase. This 
indicates, cardiac function improvement at late phase in fingolimod treated groups 
* 
** 
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as compared to control group is due to anti-apoptotic and anti-inflammtory pathways 
activation.  
Reperfusion after transient ischemia in myocardium leads to cardiomyocytes 
apoptosis and cardiac dysfunction
224, 225
. TUNEL positives nuclei staining i.e gold 
standard method
250
 to measure extinct of apoptosis have been used in this study. 
Consistently with previous results, in the transplanted group those treated with 
fingolimod 15 min before explantation of heart expressed a lower frequency of 
TUNEL positive nuclei as compared to control. That indicates the cardioprotective 
role of fingolimod by activating anti-apoptotic cascade.  
One of the primary targets with this drug is to mitigate apoptosis in I/R. The 
molecular signalling RISK and SAFE pathways activation have been reported with 
fingolimod 
138, 175
. The RISK (Akt1/2, Erk1/2, and GSK 3β) and SAFE pathways 
(JAK and STAT3) are the main sources for regulation of apoptotic pathways 
because of control on mitochondrial permeability transition pore 
3, 173, 174
.  The m 
PTP opening is vital step in apoptosis.  Consistent with previous findings, activation 
of RISK and SAFE signalling pathways observed following decreased level of 
apoptosis in the treated group as compared to control. The inhibition of pro-
apoptotic protein Bax, enhanced immunostaining for anti-apoptotic protein Bcl-2 
found after 24 hours of reperfusion in heterotopic transplanted heart tissue.  
According to literature, S1P and its agonist has important role in reduction of 
inflammatory mediators in I/R injury. Different models have been tested for 
immunosuppression including the porcine model of I/R, and spontaneous obstructive 
coronary atherosclerosis murine model showed the better myocardial protection and 
decrease inflammatory markers in the fingolimod-treated group. We measured 
inflammatory response in blood and tissue. In blood, we found the reduction of 
neutrophils and lymphocytes. Recent studies have demonstrated the significance of 
immune system role in I/R injury. Carlos G et al
185
 found improved myocardial 
salvage in animals using fingolimod and suggested an immunomodulatory role of 
fingolimod by activation of S1P receptors. 
185
.  The Inflammatory mechanism is one 
of the key factors in I/R injury. The ICAM-1, IL-6, and TNF-α contribute in as a 
pro-inflammatory cytokines to develop myocardial damage
228-230
. The correlation 
between anti-inflammatory effects of fingolimod with cordioprotection is evident in 
our experiment. While anti-inflammatory effect of fingolimod is well established as 
its approved drug for multiple sclerosis. 
This is well established that ischemia-reperfusion cause myocardial injury due to 
oxidative stress
251,252
. This drug also decreases oxidative stress in the ischemia-
reperfusion
11,27
. The reduction in oxidative stress mediated by both RISK and SAFE 
pathways
185
. Oxidative stress is another major element involved in apoptosis. In our 
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transplantation study, we found decreased level of malondialdehyde and reactive 
oxygen species in the fingolimod-treated group.  
Myocardial ischemia-reperfusion also produces nitric oxide synthase, that release 
nitric oxide which reacts with ROS, as a result, forms toxic substance peroxynitrite 
that also behaves as ROS leading to necrosis and apoptosis
253
. Fingolimod treatment 
partially attenuates nitrative stress in transplanted myocardium
254
. Present findings 
suggest fingolimod can be efficiently used as a preconditioning agent to improve 
myocardial salvage. 
Together, all these results are suggestive of the myocardial protective role of 
fingolimod in global ischemia-reperfusion. Fingolimod is the only available FDA-
approved agent, containing S1P receptors for prevention of multiple sclerosis 
relapses. This experimental study has the potential for translation into clinical trials. 
6.5. Conclusion 
In conclusion, our study supports the cardioprotective role of sphingosine 1-
phosphate structural analogue fingolimod for reduction in apoptosis and 
inflammation in an experimental model of heterotopic heart transplantation. We 
found preservation of high energy phosphates at early phase of reperfusion 
associated with fingolimod treatment. This study provides insight for activation of 
cellular signaling pathways including Akt1/2 and ERK1/2 following improved 
mechanical activity of myocardium by assessment of left ventricular end diastolic, 
systolic pressures and positive and negative maximal contractility at late phase of 
reperfusion. 
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SECTION-IV 
                         7. GENERAL DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
127  
7.1. Restatement of the Hypothesis 
 
The main hypothesis was that an intravenous bolus of fingolimod would provide 
cardioprotection from ischemia-reperfusion injury by preservation of HEP,  reducing 
inflammation, apoptosis and activating survival pathways. In addition, it was 
hypothesized that fingolimod would preserve hemodynamic function after global 
ischemia-reperfusion by reducing myocardial damage. While a few studies have 
recently used fingolimod for cardioprotective role against regional ischemia 
reperfusion therapy.  According to our best knowledge,  effect of fingolimod on global 
ischemia reperfusion injury has never been studied before. In this thesis, we studied the 
effect of fingolimod on cardiac arrest and resuscitation, cardioplegic arrest 
(cardiopulmonary bypass) and cardiac transplantation models.   
An intravenous infusion of fingolimod administered before ischemia offered better 
protection from apoptosis in cardiomyocytes and tissue necrosis than without drug 
(Section III B and C). When the fingolimod infusion was given in early 
reperfusion(Section III-A), significantly anti-inflammatory and anti-apoptotic effects 
have been observed but relatively less as compared to pre-ischemic treatment  and 
hemodynamics were also improved in both protocols at late phase of reperfusion, 
that indicates fingolimod do not have inotropic property and late phase 
hemodynamic improvement suggests improved myocardial salvage. The difference 
between pre and post pharmacological conditioning with fingolimod demonstrated 
no statistically significance. Although, in heterotopic cardiac transplantation, the 
cardioprotective effect was relatively lesser than other models, where ischemic time 
were 10 minutes.  But still in transplantation group, results were significantly improved 
as compared to control group.  
 
From this thesis, it can be concluded that fingolimod play cardioprotective role by  
preservation of high-energy phosphates, reduction in oxidative stress along with 
inhibition of apoptosis and inflammation in ischemia and reperfusion injury. 
Fingolimod therapy  maintained [ATP] after ischemia and reperfusion by changes 
relatively near to the baseline. According to Hofmann U et al
283
, a post ischemic 
treatment do not reduce infract size and increased mortality rate due to pro-arrhythmic 
property, while in pre and post ischemic treatment  group, pro-arrhythmic property was 
canceled because it‟s connected with only first dose. In our study, results are suggestive 
about cardioprotection as also reported by Santos Gallego et al. in his study by 
demonstrating regional cardioprotection 
185
. 
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7.2. Possible mechanism of cardioprotection by Fingolimod 
The work in thesis indicates possible mechanism of cardioprotection by fingolimod 
in global ischemia reperfusion injury (Figure.7.1).  
7.2.1. Anti-apoptotic role of fingolimod 
Fingolimod demonstrated significant beneficial outcomes in ischemia reperfusion 
injury, more specifically to reduce reperfusion injury. During any myocardial ischemia 
reperfusion event, finally upto 50% contribution is caused by reperfusion injury, and in 
some cases like sudden cardiac arrest, where we can not prevent ischemic injury but 
reperfusion injury can be reduced by using pharmacological cardioprotective agent. 
Fingolimod shows promising results to deal the above issues, 
because in reperfusion, major issue is apoptosis and mPTP is final and and important 
step in I/R injury to cause extensive apoptosis. Main pathways to inhibit mPTP 
opening are the RISK and SAFE signaling  pathways 
3, 173, 174
. It has been proved that 
fingolimod may activate these pathways 
138, 175
. In our all experimental models of 
global ischemia reperfusion, Akt1/2 and Erk1/2 demonstrated significant 
phosphorylation as compared to control group after 1 hour and 24 hours of reperfusion.  
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Figure 7.1 Cardioprotective mechanism of fingolimod 
Therefore, the current study suggests that fingolimod may serve as a potential 
reperfusion therapy by preventing apoptosis through RISK and SAFE signalling 
pathways. In our rat models, consistent with the results of RISK and SAFE pathways 
activation; reduced apoptosis in TUNEL assay, increased expression of antiapoptotic 
protein and reduced expression of proapoptotic expression have been found. In 
previous studies, these pathways have been verified by using inhibitors of these 
pathways, wortmannin (RISK inhibitor) and AG490 (SAFE inhibitor)
185
,  suggesting 
the cardioprotective mechanism mediated through RISK and SAFE pathway. 
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7.2.2. Anti-Inflammatory role of fingolimod 
Inflammatory mediators are one of major factors contributing towards ischemia 
reperfusion injury. Fingolimod showed adequate anti-inflammatory effect in our all 
ischemia reperfusion models. Santos et al. and Hofmann U et al. both achieved anti-
inflammatory effects of fingolimod in ischemia reperfusion models. On the basis of 
known anti-inflammatory actions of fingolimod in multiple sclerosis 
284, 285
, it may also 
be useful to reduce the inflammatory response to ischemia-reperfusion injury 
185, 283
. 
Fingolimod is a potent immune modulator by inhibiting the activation of neutrophils 
286
, monocytes 
287
 and lymphocytes, which can lead to necrosis of cardiomyocytes 
288
. 
A study by Nakamura et al., 
289
 confirmed that there is a significant apoptosis in 
myocardical cell induced by neutrophil infiltration. 
In summary, the effects of fingolimod to reduce ischemia-reperfusion injury could 
also be applied to reducing the adverse effects of the inflammatory process which 
includes attenuation of the production of free radicals, reduction in capillary plugging 
and minimizing the direct injury to cardiomyocytes. 
 
7.3. Limitations and clinical significance of fingolimod therapy 
Despite of all advances in cardiovascular sciences, ischemic heart disease continues to 
be the leading cause of mortality and morbidity in developing as well as developed 
world (World Health Organization 2016).  According to a  study, acute coronary 
occlusion will be the most common cause of death in the entire world by 2020 
290
.  All 
these patients may undergo one of the following events 1) PCI, 2) CABG, 3) Sudden 
cardiac arrest, 4) myocardial infarction leading to heart failure that need heart 
transplantation in severe cases. Although with advances in percutaneous techniques, 
majority of the patients undergo PCI but still CABG is main stay of treatment in 
complex coronary artery disease and/or with valvular diease. That expose to global 
ischemia and reperfusion as cardioplegic arrest for open surgery.  
 
 
The work presented in this thesis may offer a new attractive therapeutic strategy that 
may contribute to myocardial protection in reperfusion injury. Although, usually it‟s 
not easy to translate potential therapeutic treatment from animal to clinical settings 
due to multiple factors mainly including mass specific metabolic rate difference, 
receptors expression difference in different species 
291
, and electrophysiological 
properties 
292
. Indeed, rat have higher metabolic and extremely short half- life of 
fingolimod, while in human half-life is much longer. Consideration of all these 
factors make translation challenging but as this drug is already in human use with 
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mimimal serious adverse effect that gives hope to overcome challenges. 
In rat models, infection rate and complications due to infection cannot be studied 
because of high resistance to infections in rats. It needs to be considered prior to 
human translation of fingolimod because it may cause lyphmphopenia that increases 
the risk of infection. 
Another precaution in comparing data on rats and humans, are differences in collateral 
circulation of the heart. However, since humans have a greater collateral circulation 
than the rat 
293
, in human better cardioprotection can be expected using fingolimod 
as compared to rat models. Further experiments are already underway to test this 
hypothesis. 
 
7.4. Concluding remarks 
 
In conclusion, this study has provided evidence that fingolimod infusion is 
cardioprotective in sudden cardiac arrest, cardiopulmonary bypass and cardiac 
transplantation in  in vivo rat model. Moreover, the concept may have therapeutic 
potential for the treatment of reperfusion injury by acting on apoptotic pathways, 
inflammatory cascades and activation of survival pathways that consequenctly 
preserves high energy phosphates and cardiac function. This thesis has identified a new 
potential pharmacological pre and post conditioning drug for cardioprotection in global 
ischemia-reperfusion. 
 
In summary, the potential use of fingolimod may therapeutically involve in 
cardioprotection in global ischemia reperfusion injury in cardioplegic arrest, sudden 
cardiac arrest with ECLS and during heart procurement and transplantation by, 
 
i. Attenuation of apoptosis by inhibition of pro-apoptotic and activation of anti-
apoptotic cascades. 
ii. Inhibition of pro-inflammatory cytokines and inhibition of complement system 
activation. 
iii. Protecting cardiomyocytes by attenuation of neutrophil infiltration in response to 
ischemia reperfusion injury. 
iv. Activation of Akt1/2 and Erk1/2 signalling survival pathways (RISK and SAFE 
pathways). 
v. Reduction in reactive oxygen species and nitrative stress 
vi.  In consequences of all above mechanisms, preservation of high energy phosphates 
and myocardial salvage. 
vii. Due to myocardial salvage, ultimate goal can be achieved i.e. preservation of 
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mechanical function of heart. 
 
At the end, we speculate that, given mechanisms for cardioprotection by fingolimod 
may open new windows for prevention of global ischemia-reperfusion injury.  
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